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ABSTRACT OF THE DISSERTATION 
Design, Synthesis and Characterization of Lipidated PNA-peptide Conjugates as Potential Therapeutic 
and Diagnostic Reagents 
 by  
Yinyin Song 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2011 
Professor John-Stephen A. Taylor, Chairperson 
 
    Peptide Nucleic Acids (PNAs), are an ideal choice for antisense and antigene tools and probes 
because of their stability and high binding affinity, but have limited application as therapeutic and 
diagnostic agents because of poor membrane permeability. To increase membrane permeability, we 
conjugated hydrophobic lipids or phospholipid molecules and hydrophilic cell penetrating peptides to 
the N and C terminus of PNAs, and studied their physical and biological properties. 
After solid-phase automated synthesis, PNA-CPPs (TAT/Arg9) were coupled with lipids or 
phospholipids before cleavage from the support and then purified by HPLC. The conjugates were 
characterized by UV-vis and MALDI, and by their ability to form vesicles in water and to partition 
between water and octanol. The size of the vesicles formed was determined by DLS. One of the 
Lipid-PNA-TAT conjugates was further tested in vivo as a potential PET imaging reagent after 
radiolabeling with bromine-76. 
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Chapter 1 
Introduction 
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1.1 Peptide nucleic acids (PNAs) as therapeutic and diagnostic agents 
    In a living cell, genetic information is transferred from dsDNA (double-stranded DNA) to mRNA 
by the process of transcription and then from mRNA to protein by the process of translation.  Thus, 
antigene technology refers to methods for inhibiting transcription, while antisense technology refers to 
methods for inhibiting translation. 
    Peptide nucleic acid (PNA) was first invented and reported by Peter Nielsen and colleagues in 
1991 as a third-generation antigene and antisense oligonucleotide analog for applications in diagnosis 
and therapy. [1, 2] Stucturally designed as a hybrid of peptide and DNA, PNA is constructed with a 
charge neutral peptide backbone and nucleic acid bases, which enable them to Watson-Crick base pair 
with complementary DNA (deoxyribonucleic acid), RNA (ribonucleic acid) or PNA oligomers (Figure 
1.1). 
N N
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Figure 1.1 Structures of PNA, DNA and RNA. 
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    Due to its neutral non-native peptide backbone, PNA has a number of attractive features for the 
development of probes and drugs. The neutral backbone of PNA eliminates electrostatic repulsion with 
a complementary DNA or RNA, thereby improving the binding affinity of PNA for DNA and RNA. 
Thus PNA-DNA or PNA-RNA duplexes are thermodynamically more stable than corresponding 
DNA-DNA and DNA-RNA complexes, [3-5] and retain sequence specificity, being able to form 
duplexes with complementary DNA or RNA by Watson-Crick base-pairng. (Figure 1.2) Because of its 
neutral charge and high binding affinity, PNA can also invade regions of secondary structure, and thus 
can bind complementary RNA or DNA sequences with great affinity and specificity, independency of 
ionic strength.  Also due to its non-native peptide backbone PNA is not susceptible to degradation by 
nucleases and proteases and does not activate RNaseH degradation of a target mRNA. 
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Figure 1.2 Watson-Crick Basepairs for PNA-DNA and PNA-RNA Duplexes 
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Figure 1.3 Watson-Crick and Hoogsteen Basepairs for PNA-DNA and PNA-RNA Triplexes. 
    PNA was originally expected to form a conventional triplex complexes with duplex DNA, 
PNA•(DNA)2, with a homopyrimidine PNA strand binding to the major groove of the ds-DNA helix 
via Hoogsteen base pairing. However, actually it turned out that a triplex invasion complex of the form 
(PNA)2•DNA was formed, in which one PNA strands binds to the homopurine DNA stretch by 
standard Watson-Crick base-pairing in an antiparallel orientation, while a second PNA strand binds the 
PNA-DNA duplex by Hoogsteen base-pairing probably in a parallel orientation (Figure 1.3). The 
triplex invasion complexes are very thermally stable with a Tm of more than 85°C, but the formation is 
slow and pH-dependent at physiological concentrations of salt, because cytosine needs to be protonated 
to be able to engage in Hoogsteen binding. 
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Figure 1.4 Four Types of Pseudocomplementary Basepairs Involved in Forming PNA Double 
Duplex Invasion Complexes 
An alternative approach to targeting double stranded DNA involves designing PNAs that are 
complementary to each DNA strand, but that have little affinity for each other.  Since the 
2,6-diaminopurine / 2-thiouracil base pair is very unstable due to steric hindrance resulting from the 
replacement the oxygen with sulfur, two pseudo complementary PNA sequences cannot bind each 
other well, but can bind their DNA complement very well (Figure 1.4). Thus, after adenine and 
thymine are substituted with 2,6-diaminopurine and thiouracil respectively in all A/T base-pairs of 
PNA, double duplex invasion by pseudo complementary PNAs can take place.[6] 
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Triplex Triplex Invasion Duplex Invasion Double Duplex Invasion  
Figure 1.5 Different Structural Modes for Targeting Doubled Stranded DNA with PNA 
Oligomers. 
    To test the diagnostic and therapeutic potential of PNA, experiments were initially conducted in 
cell-free in vitro systems.  As an antigene agent, PNA can bind the DNA template strand to form an 
invasive triplex complex, which results in complete arrest of mRNA elongation because of steric 
hindrance blocking the RNA polymerase. [7]  PNA can also inhibit transcription by forming a triplex 
with a transcription factor binding site as shown for NF-kB transcription factor. [8]  However, effective 
inhibition of transcription has not been shown to occur with double duplex invasion PNAs, which are 
formed by pseudo-complementary PNA binding to both the template and the non-template strand, 
probably because the RNA polymerase is able to disrupt the PNA-DNA duplexes and to continue 
transcription (Figure 1.5). [9] 
    As antisense reagents, PNA can arrest translation by forming duplexes and triplexes with mRNA. 
When PNA is targeted to positions near the start codon, translation initiation can be almost completely 
inhibited by a PNA binding duplex. [10-12]  PNA can also bind at intron-exon junctions of pre-mRNA 
to form duplexes that inhibit RNA splicing reactions and thereby block maturation of the mRNA.[12] 
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1.2 Synthesis of PNA and PNA-conjugates 
With the refinement of solid-phase PNA/peptide synthesis protocols and commercially available 
PNA monomers and amino acids, PNA and PNA-conjugates can be assembled on the solid support by 
Fmoc chemistry, as shown in Figure 1.6. [13] 
    Although the solid-phase methods are convenient and efficient, the small losses in each of the 
numerous coupling and deprotection steps place a practical upper limit to the maximum length of a 
PNA or PNA-conjugate. Thus, direct solid-phase synthesis is not practical for the assembly of longer 
PNA and PNA-conjugates. Furthermore, the accumulation of truncated oligomers may result in 
difficult purification and low overall yields. 
Resin Fmoc Deblocking
WASH
WASH
WASH
Fmoc Deblocking
20% Piperidine / DMF
PNA-CPP on resin
Activating and Coupling / Capping
0.2M HATU, 0.2M Monomer, Base;
5% Ac2O, 6% 2,6-lutidine, DMF
 
Figure 1.6 Fmoc Solid-phase Synthesis of PNA and PNA-peptide Conjugates 
Fragment ligation is an alternative strategy for the assembly of PNA and PNA-conjugates. [14] 
This strategy entails the synthesis and purification of PNA and the molecule to be conjoined. Then 
these two fragments are subsequently joined chemoselectively under the conditions that are compatible 
with the nucleobases and with the molecule to be conjoined. Different chemical ligation methods have 
 7 
 
been used, including disulfide bond formation, thio-maleimide linkage formation, and amide bonds 
formation (Figure 1.7). 
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Figure 1.7 Structures of Linkages between PNA and Peptides: Disulfide, Thio-maleimide, Amide 
and Oxime Linkage. 
 
1.3 Intracellular delivery of unmodified PNAs and modified PNAs 
    Because PNA is not membrane-permeable due to its size and neutral-charge backbone it does not 
spontaneously enter eukaryotic cells [22] and many methods have been developed to facilitate its entry. 
1.3.1 Methods for intracellular delivery of unmodified PNAs 
    The first intracellular delivery method of unmodified PNA as antisense agent was by 
microinjection, and was used to inhibit the expression of SV40 large T antigen. In microinjection, a 
holding pipette was used to immobilize the cell by suction, and then the PNA solution was injected into 
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the cell nucleus or cytoplasm via an injection pipette under pressure. Immuno-cytochemistry showed 
that PNAs were able to suppress T-Ag expression by for around 40% and 50%, [10] with at an 
intracellular concentration of about 1μM. Although microinjection proved to be an effective tool, it was 
only applicable for small-scale experiments as a laborious technique (Figure 1.8). 
nulceus
Pressure to add PNA
Pressure to add PNA
suction to fix the cell
cytoplasm
 
Figure 1.8 Microinjection to deliver PNA into cells 
    The second method of for intracellular delivery of unmodified PNA was by electroporation as 
illustrated by the 60% inhibition of telomerase activity by anti-telomerase PNAs in SV40 transformed 
fibroblasts . [15] The potential of PNA to specifically modulate the constitutive and alternative splicing 
of murine interleukin-5 receptor-a (IL-5Ra) pre-mRNA was also demonstrated using electroporation. A 
PNA was designed to inhibit splicing of exon 9 in the IL-5Ra pre-mRNA in a murine B lymphoma cell 
line which was expected to decrease IL-5Ra membrane isoform transcript expression and enhance 
expression of the soluble IL-5Ra isoform transcript. In vitro Experiments in cell culture showed a PNA 
sequence and dose specific repression of the membrane isoform mRNA which could be completely 
suppressed at 10μM PNA (Figure 1.9). [16] 
nulceus
1 Add PNA to media
2 Apply electronic pulses on needle 
electrodes to create electronic fields, which  
temperarily form openings on cell membrane
cytoplasm
PNA
PNA
3 PNA enter cells via
the temperary openings,
then cells go back to
normal shape  
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Figure 1.9 Electroporation to deliver PNA into cells 
    A third way of delivering unmodified PNA to cells was described by Corey’s group [17], which 
took advantage of an established method for DNA transfection that makes use of cationic liposomes.  
In their approach, anti-telomerase PNA was hybridized to partially complementary DNA oligomers to 
render them negatively charged, and then using the cationic lipids to transfect the PNA/DNA 
complexes into cells. And they showed a subsequent study that the terminus of the 5’ untranslated 
region of luciferase could be efficiently reached by lipid-mediated transfection of PNA/DNA 
complexes (Figure 1.10). 
PNA:DNA Hybrid
PNA:DNA
Nuclei
PNA:DNA
cell membrane
1 Endocytosis 2 Formation 
of endosome
Cationic Acid
+ PNA:DNA Complex PNA:DNA Complex
3 Endosome
Escape
 
Figure 1.10 Cationic lipid-mediated transfection of PNA•DNA duplexes into cells 
    In some cases, unmodified PNAs can be directly taken up by cells, but this is not general and 
depends on the particular cell. For example, the Escherichia coli mutant strain AS19 containing a cell 
wall/membrane defect was able to uptake. PNA in micro molar concentrations as evidenced by specific 
inhibition of ribosomal RNA and translation of β-galactosidase and β-lactamase. [18, 19] Direct uptake of 
PNAs also occurs in some eukaryotic cells. In one case, PNA that was complementary to HIV_1 
gag-pol in HIV-1 infected human lymphoma cell line H9, led to an effective disruption of ribosome 
frameshifting. [20] 
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1.3.2 Intracellular delivery of modified PNAs 
    In order to improve PNA transport into the cell, PNAs have also been modified to facilitate 
intracellular PNA penetration of cell membranes. Herein three main types of modifications are 
described and evaluated. 
Lipophilic Conjugates 
    The first type of modification to be discussed is conjugation of PNA to lipophilic moieties, like 
adamantyl, triphenylphosphonium, cholesterol and cholic acid. The delivery efficiency of PNA 
modified with the adamantyl group was dependent on the cell type and the specific PNA sequence, as 
monitored by laser confocal microscopy analysis. Attempts to use adamantyl modified PNAs to 
suppress genes in a leukemic cell line NB4 were not very successful, however (Figure 1.11). [21, 22]  
O NH
O
PNAH2N Fluorescein
Adamantyl
 
Figure 1.11 Adamantyl acetyl modified PNA conjugate 
    The intracellular uptake of PNA conjugates modified with triphenylphosphonium cation was 
tested in human osteosarcoma cells, human fibroblast cells and isolated mitochondria by methods such 
as confocal microscopy, immunogold-electron microscopy, and cell fractionation with immunoblotting. 
The results indicated that after enough mitochondrial uptake of the ph-PNAs took places with adding a 
concentration of 1μM of PNA conjugate during mitochondrial replication, the PNA conjugate cannot 
bind its target during replication of mitochondrial DNA in vivo (Figure 1.12). [23]  
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Figure 1.12 Triphenylphosphonium modified PNA conjugate  
Cholesterol and its analogues are highly lipophilic molecules have been used to improve cellular 
delivery of oligonucleotides [24, 25], and DNAs [26, 27] as anticancer agents. The intracellular uptake 
properties of cholesterol-PNA conjugates, however, have not been proven to be as effective as 
cholesterol conjugated antisense oligonuleotide. [28, 29] 
More recently, attempts have been made to make use of steroid receptors to enhance delivery of 
PNAs. DEX-bisPNA, consisting of a dexamethasone moiety linked to a PNA clamp (bisPNA) through 
a spacer, was synthesized and selected from several bifunctional steroid derivatives. [30] DEX-bisPNA 
was shown to bind to the glucocorticoid receptor (GR) which improved the intracellular delivery of the 
PNA and its translocation from the cytoplasm into the nucleus, resulting in an enhanced GR-dependent 
expression of the targeted reporter gene. However, this delivery system was limited for cells expressing 
steroid receptors (Figure 1.13).  
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Figure 1.13 Dexamethasone modified PNA conjugate: DEX-bisPNA 
    Bile acids are also highly lipophilic and have been conjugated to PNA in an effort to improve 
intracellular delivery. One of bile acids, cholic acid, contains a 3-hydroxy group that could be used to 
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conjugate it to the N-terminus of PNA. Unfortunately, the intracellular uptake of the PNA-cholic acid 
conjugate by the bile acid transporter has not been reported as yet. Only melting temperature 
experiments have been reported showing that cholic acid weakly improved binding to complementary 
DNA (Tm = 3.5C), in contrast to DNA-cholic acid conjugates that showed a substantial increase 
(Tm = 8-11C) in the thermal stability of DNA duplexes (Figure 1.14). [31] 
H
HO
HH
H
OH
OH
O
HN PNA
Cholic acid
 
Figure 1.14 Cholic acid modified PNA conjugate 
    PNAs have also been conjugated to other types of lipophilic molecules, such as acridine, psoralen 
and anthraquinone, but for other purposes, and so their ability to enhance membrane permeability is not 
well documents. The DNA intercalator, 9-Aminoacridine, was conjugated to mono or bis-PNA to 
improve PNA strand invasion at different ion strength. [32, 33]  Psoralen is a photoreactive DNA 
crosslinker that has been conjugated to PNA to enhance its binding to DNA, by forming bonds with 
pyrimidine bases in the DNA via [2+2]-cycloaddition reactions. [34] The PNA-anthraquinone conjugate 
was synthesized and used to deduce the structures of the complexes formed between the PNA and 
DNA by identifying the strongest cleavage sites of photo-cleavage reaction (Figure 1.15). [35] 
N
NH2
O OO
O
Opsoralen
anthraquinone
9-aminoacridine
 
Figure 1.15 Structures of 9-aminoacridine, psoralen and anthraquinone 
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Receptor Ligand Conjugates 
    The second type modification was conjugation of PNA to cell-specific receptor ligands with the 
purpose of improving intracellular delivery, like lactose, dihydrotestosterone, and insulin like growth 
factor I. [36, 37] 
    Wickstrom et al [36] conjugated PNA to a peptide, which specifically targeted the cell surface 
receptor for insulin-like growth factor1 (IGF-1R). Laser confocal microscopy demonstrated that only 
IGF-1R-expressing cells internalized the conjugated PNA, however, the PNA was exclusively found in 
vesicular compartments of the cytosol (Figure 1.16). 
NH2-Gly-CCGCTTCCTTTC Gly4-Cys-Ser-Lys-Cys-CONH2
PNA-Peptide
a D-Peptide as an insulin-like growth factor1 (IGF-1R) 
Figure 1.16 PNA-Peptide conjugate containing a D-Peptide of insulin-like growth factor 
1(IGF-1R) 
    Corey et al [38] conjugated lactose to anti-telomerase PNA, since lactose can be recognized by the 
hepatic asialoglycoprotein receptor (ASGP-R). Fluorescence experiments were conducted in two cell 
lines, HepG2 as liver carcinoma derived ASGP-R expressing cells and DU145 as prostate carcinoma 
ASGP-R negative cells. Although only the ASGP-R cells internalized the PNA-lactose conjugate, the 
uptake was weak and PNA conjugate was confined to vesicular compartments of the cytoplasm. 
(Figure 1.17) 
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Figure 1.17 Structure of lactose 
    Boffa et al [37] used dihydrotestosterone (T)-PNA in two cell lines of LNACaP expressing the 
androgen receptor and the DU145 cell line that did not. Confocal scanning microscopy showed strong 
cytoplasmic and nuclear uptake of the T-PNA conjugate in LNACaP cells, while cytoplasmic uptake 
was limited in the DU145 cells. However, unmodified PNA demonstrated the opposite uptake result in 
two cell lines, making the cellular uptake of the T-PNA highly controversial (Figure 1.18). 
H3C
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2
Dihydrotestosterone (T), 
can recognized the androgen receptor  
Figure 1.18 Dihydrotestosterone-PNA-Rhodamine conjugate 
Cell penetrating peptide Conjugates 
The third type modification was to conjugate PNAs to cell-penetrating peptides, which are known 
to penetrate biological membranes. The most well-studied CPPs included penetratin, transportan, 
nuclear localization sequence (NLS), polylysine, polyarginine, HIV-1 TAT(48-58), etc., shown as 
below (Table 1.1). 
Table 1.1 Peptide sequences of penetratin, transportan, nuclear localization sequence (NLS), 
polylysine, polyarginine, HIV-1 TAT(48-58) 
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pAntp(43-58)/Penetratin : RQIKIWFQNRRMKWKK 
Transportan : GWTLNSAGYLLGKINLKALAALAKKIL 
Nuclear Location Sequence (NLS) : PKKKKRKV 
PolyLysine : (Lys)n 
PolyArginine :  (Arg)n 
HIV-1 TAT (48-58) YGRKKRRKRRR 
    PNA conjugates with penetratin have shown cell dependent differences in cellular uptake. In 
human prostate carcinoma, cutaneous melanoma, breast carcinoma, fibroblast and cervix carcinoma, 
the PNA-penetratin conjugates were found to be entrapped in vesicular compartments in the cytoplasm, 
and a very limited antisense effect was observed. The entrapment of PNAs in vesicle was shown by 
immunofluorescence studies, at a concentration of 10 μM of biotinylated penetratin-PNA conjugate. [39] 
In contrast, PNA-penetratin conjugates had a strong intracellular effect in primary magnocellular 
neuron cells. In these cells, a sequence-specific and dose-dependent down regulation of the 
prepro-oxytocin gene was demonstrated by RT-PCR (Reverse transcription-polymerase chain reaction). 
[40] And Pooga et al. demonstrated similar dose-dependent cell and sequence specific results for 
transportan-PNA conjugates. [41]  
    A 7-mer basic nuclear localization signal (NLS) peptide (PKKKKRKV) was also conjugated to 
improve the nuclear delivery of PNA in Burkitt’s lymphomas (BL) cells, containing a hyperexpressed 
c-myc oncogene. Confocal microscopy showed that only the antisense PNA-NLS conjugates labeled 
with rhodamine entered intact isolated nuclei of BL cells, and the other two groups of PNA conjugates 
with a scrambled NLS peptide or without the NLS peptide were only delivered into the cytoplasm of 
 16 
 
BL cells. The NLS antisense PNA conjugates also showed inhibition of c-myc expression by Western 
and Northern blotting. [42] BL cells were also exposed to Rhodamine-PNA-mycwt, 
Rhodamine-PNA-mycwt-NLS, or Rhodamine-PNA-mycwt-NLSscr, and analyzed by confocal 
microscopy. A 10 mM PNA-MYCwt-NLS concentration caused maximum inhibition of MYC 
expression of 75 % with only a 25 % decrease in cell viability, although a 30% decrease was already 
observed at 5 mM. The three panels were first used to show the phase contrast images of the optical 
section crossing the middle of the nuclei, and the three panels were then used to show the fluorescence 
images, and the three bottom panels were finally used to show the superimposed images of the phase 
contrast and fluorescence images. 
Polylysine or lysine was also investigated for its ability to enhance intracellular delivery of PNA 
in HeLa cells (named after a patient died of cancers called Henrietta Lacks) by monitoring the 
production of enhanced green fluorescent protein gene (EGFP) which would only be expressed in the 
presence of the splice-correcting Lys-PNA conjugate. High levels of EGFP were observed in the 
presence of 1-10μM of PNA-(Lys)n conjugates.[43] 
 
1.4 Mechanism of intracellular delivery of PNA by cell-penetrating peptides 
    Cell-penetrating peptides (CPP), are short sequences of peptides that can facilitate entry of 
attached molecules into cells. To be classified as a CPP, a peptide needs to be shown to enter cells by at 
least three different assays. [44] CPPs can be divided into families or subgroups: protein derived (P), 
chimeric (C), and designed/synthetic (S). The largest family is the protein-derived CPPs. Penetratin or 
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pAnt, as a homeodomain-derived peptide, is important among this first family. Homeoproteins are 
defined as a class of transcription factors that bind DNA through a common protein structure of 60 
amino acids in length, called the homeodomain. The next family of CPPs is the chimeric peptides that 
are partly derived from naturally occurring peptides or proteins, and partly derived from synthetic 
peptides. The final family of synthetic CPPs is a type that have been designed and synthesized to 
facilitate the intracellular delivery, like the “model amphipathic peptide” (MAP) which forms 
amphipathic alpha helices, or polylysine and polyarginine that bear multiple positive charges. 
    There are three principal mechanisms [45] proposed to be involved in transporting molecules across 
the boundary cellular membranes, such as passive or gradient diffusion, facilitated diffusion, and active 
transport (Figure 1.19). 
High concentration
Low concentration
Passive Diffusion Facilitated Diffusion
Regulated according 
to Needs of cells
Active Transport (I)
Low concentration
outer side of cells
inner side of cells
outer side of cells
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transmembrane protein 
and ATP needed
transmembrane protein needed
inner side of cells
 
Figure 1.19 Three principal mechanisms of (1) passive diffusion, (2) facilitated diffusion and (3) active 
transport (I) for intracellular delivery of molecules through the cell membrane 
    Passive diffusion (Figure 1.19) is a spontaneous process in which the random motions of 
molecules or other particles move across the cell membrane from the outside region of high 
concentration into the inside region of lower concentration. The diffusion rate is dependent on the 
temperature, the molecular weight, and the differences between the outer and the inner concentrations 
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of the molecule. This mechanism is usually used by small molecules without much selectivity. 
    Facilitated diffusion (Figure 1.19) is a transport process that is assisted by specific transmembrane 
integral proteins, and is not energy-dependent. In this case, the transmembrane proteins are 
ion-channels for ions or small molecules needed by the cell, and which are regulated by molecules 
binding to cell receptors. 
    Active transport is a transmembrane delivery system for molecules into cells or cell organelles 
from a region of low concentration to a region of high concentration, requiring of ATP (adenosine 
triphosphate) as cellular energy source. Two main types of active transport have been characterized, 
one involving direct movement of a molecule across the cell membrane with assistance from transport 
proteins, and another involving endocytosis in which the membrane engulfs molecules and then folds 
into a vacuole or vesicle that enters the cell (Figure 1.19 and 1.20). 
PNAs PNAs
Nuclei
PNAs
cell membrane
1 Interaction with
cell membrane
2 Formation 
of endosome
3 Endosome
Escape
Active Transport (II)
ATP needed  
Figure 1.20 Mechanism of active transport (II) of molecules into cells 
    Since the transport mechanism of passive diffusion is limited by molecule size, this mechanism is 
not utilized by CPPs. Thus, CPPs enter cells either by facilitated diffusion or endocytosis. It was first 
proposed that CPPs, especially penetratin, poly-Arg and TAT [46-48], could pass through the plasma 
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membrane via an energy-independent pathway of diffusion. 
    However, this mechanism became less popular when the entry mechanism for the TAT and the 
poly-arginine CPPs were re-evaluated by Lebleu B. et al [49], according to their evidences of fixation 
artifacts during the preparation of samples for microscopic observation, thus it was argued that CPPs 
and /or their cargoes can cross cell-membrane through endocytosis. In their fluorescence microscopy 
experiments, HeLa and CHO cells were either fixed with formaldehyde or left untreated. In the unfixed 
cells, small fluorescence spots were found in the cytoplasm providing as the first evidence that 
intracellular delivery of PNA-CPP conjugates was occurring by endocytosis. 
    Following this initial study, the mechanism of endocytosis of various CPPs with or without 
attached cargoes was extensively studied. 
    Three major endocytosis pathways [50] were identified as clathrin-mediated, caveolin-mediated and 
macropinocytosis, although the endocytosis process was actually more complex and involved a large 
network of protein-protein and protein-lipid interactions. 
    The clathrin-dependent endocytosis pathway [51] begins on the plasma membrane with a gradual 
invagination and formation of clathrin-coated vesicles, followed by its release into the cytoplasm. This 
pathway can be inhibited by potassium depletion or treatment with chlorpromazine as inhibitors. When 
HeLa cells were treated with chlorpromazine and Alexa-Fluor 488-tagged TAT peptide, a 50% 
inhibition of peptide uptake was observed. Similarly, HeLa cells treated with the Alexa-Fluor 
488-tagged TAT peptide in potassium-free buffer resulted in a 40% inhibition of peptide uptake 
indicating that some of the uptake was due to the clathrin-dependent endocytosis pathway. 
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    The caveolae-mediated endocytosis pathway [52] is involved in the intracellular signal transduction 
of raft-associated molecules. Caveolae are defined as small (50–70 nm) invaginations in the plasma 
membrane that constitute a subclass of detergent-resistant membrane domains with many cholesterol 
and sphingolipids. This caveolae-mediated endocytosis pathway [52] was shown to be involved with 
HIV-1 TAT fusion proteins proven with by Giacca et al. Transferrin is known to be internalized by 
binding to clathrin-coated invaginations on the plasma membrane which eventually detaches to form 
the clathrin-coated vesicles in cells, and can be disrupted by Triton X-100 extraction. In the presence of 
Triton X-100, no vesicles containing fluorescently labeled transferrin or TAT fusion proteins were 
observed, but could be observed in its absence, demonstrating the involvement of clathrin-dependent 
endocytosis of TAT peptide. When cells were treated with methyl-β-cyclodextrin (MβCD), a drug that 
extracts cholesterol from cell membranes and disrupts the lipid rafts for endocytosis TAT fusion 
proteins remained on the cell membrane without the apparent endocytosis. In contrast the 
internalization of transferrin was not affected by the drug. 
    Macropinocytosis is a receptor-independent form of endocytosis caused by plasma membrane 
ruffling. Macropinocytosis was demonstrated to occur for CPP conjugated large molecules with MW > 
30,000 Da by Dowdy et al through confocal microscopy experiments.[53] In their experiments three 
macropinocytosis inhibitors were used to determine if peptides entered cells by lipid raft-mediated 
macropinocytosis, such as methyl-β-cyclodextrin (MβCD) which depletes cell surface associated 
cholesterol required to form lipid rafts, cytochalasin D as an inhibitor of F-actin, and EIPA as an 
inhibitor of the Na+/H+ exchange in the macropinosome formation. Treatment of cells with those three 
macropinosome inhibitors resulted in dose-dependent reduction of TAT peptide uptake. These 
 21 
 
observations demonstrated that lipid raft-mediated macropinocytosis was the endocytosis pathway by 
which TAT peptide to entered cells. 
    In order to improve the delivery efficiency of CPPs into the cytoplasm via endocytosis pathways, 
methods for enhancing endosomal escape were investigated. Endosome escape was reported to be 
facilitated by decreased endosomal pH, and inhibited by increased endosomal pH by Gellman et al. [54] 
No uptake of Flu-TAT or Flu-β-(VRR)4 was seen in the presence of azide and deoxyglucose, but was 
observed upon prior treatment with 50 mM ammonium chloride for 30 min to lower the pH. These 
results demonstrated that endosome escape was facilitated by decreased endosomal pH by the addition 
of ammonium chloride. 
    In 2005 Nielsen and coworkers [55] reported that Ca2+ ion can effectively improve the intracellular 
delivery efficiency of CPP-antisensePNA conjugates. They found that a similar increase in intracellular 
uptake was obtained from using 6 mM of Ca2+ as from 120 μM of chloroquine (CQ). Chloroquine 
concentrations were typically used to raise vacuolar pH to facilitate endosomal release. 
    Another hypothesis [56-58] has been proposed to explain the efficiency by which cell penetrating 
peptides insert into membranes that was based on the thermodynamics for insertion of the peptides into 
the lipid bilayer from the surface bound state. The difficulty in predicting the thermodynamic 
properties from the sequence could explain the apparent lack of correlation between sequence and 
efficiency of entry, and partly agrees with the observations that the efficiency is cell-type or 
cargo-specific. The possibility that the thermodynamics of insertion could be used to predict the 
efficiency of membrane penetration raised interest in using theoretical calculations to help in the design 
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of more effective CPPs. 
    Theoretical calculations to predict properties such as peptide binding and insertion into 
membranes using the Wimley-White hydrophobicity scales were developed by White and collaborators. 
The method of calculation using these scales was implemented in the Membrane Protein Explorer 
(MPEx) program, which is freely available through the Internet. [59] 
    They initially proposed that the probability of insertion of amphipathic α-helical peptide was 
related to the difference between the free energies of transfer between the POPC membrane interface 
and the hydrophobic interior of the bilayer [60]. These free energies can be estimated using the 
Wimley-White interfacial and octanol hydrophobicity scales, ∆Gif and ∆Goct. 
Then they tentatively proposed that a value of ∆Goct-if = ∆Goct − ∆Gif ≤ 20 kcal/mol would be the 
threshold for the successful insertion of peptide into cytoplasm membrane. If the value of ∆Goct-if was 
below this value, the peptide would be able to insert transiently into the lipid bilayer probably through 
a small transient pore followed by some membrane reorganization. Some of the theoretically calculated 
values are provided below as benchmarks for CPP design, with the secondary structure of CPPs shown 
in parentheses. (Table 1.2) 
Table 1.2 Theoretically calculated Gibbs free energy values for some CPP peptides 
Penetratin: ∆Goct-if = +16.9 kcal/mol (60% helix) 
TAT: ∆Goct-if = +19.4 kcal/mol (unstructured) 
Tp10W: ∆Goct-if = +17.1 kcal/mol (60% helix) 
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Nonalysine: ∆Goct-if = +20.8 kcal/mol (unstructured) 
Nonaarginine: ∆Goct-if = +13.6 kcal/mol (unstructured) 
    The magnitudes of the Gibbs free energies of binding and insertion, however, would be affected 
by the presence of negatively charged lipids in the membrane and specific tertiary structure like 
hydrogen bonds in the CPP peptides. At this point, the ∆Goct-if can only be used as a qualitative measure 
to compare CPPs, but not as a quantitative one, as there is too much difference between the theoretical 
calculation of Gibbs free energy values and the experimental values determined from the dissociation 
constants (KD). 
    The experimentally obtained the Gibbs free energy values were determined from dissociation 
constants KD from the equation of ∆G = RT lnKD. The Gibbs free energy values obtained then need to 
be modified by adding the cratic correction (thermodynamic correction from octanol to water) of - 2.4 
kcal/mol and the electrostatic correction of - 4 kcal/mol depending on the CPP, leading to the equation 
∆G = RT lnKD – 2.4 kcal/mol – 4kcal/mol. The experimentally derived values can then be compared 
with the theoretical calculations using the Wimley-White interfacial scale [61]. 
While the theoretical calculations and the experimentally determined Gibbs free energy values are 
often not the same, they could be quite useful in designing new CPP with improved cell penetrating 
efficiency. 
 
1.5 Choice of TAT as CPP to improve intracellular delivery 
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Figure 1.21 Physical domains of the 101-amino acid HIV-1 TAT protein 
    Given the large number of cell penetrating peptides that one could choose to enhance penetration 
of a diagnostic or therapeutic PNA, a decision had to be made as to which peptides to choose for the 
purpose.  Among these, the TAT peptide appeared to be the best choice as discussed below. 
    Human immunodeficiency virus type 1 (HIV-1) is the etiological agent for the acquired 
immunodeficiency syndrome (AIDS). HIV-1 is a retrovirus that encodes a small nuclear transcriptional 
activator protein (TAT), which can be viewed as containing five physical domains [62,63] (Figure 1.21). 
Domain 1 (1-20 amino acids) consists of an acidic N-terminal region important for transactivation. 
Domain 2 (21-40 amino acids) contains a cysteine-rich DNA-binding region with a zinc-finger motif. 
Domain 4 (49-86 amino acids) has a basic region responsible for nuclear import (Figure 1.21). The 
TAT-derived peptide fragment receiving most attention as cell-penetrating peptide is in domain 4, 
which encompasses the whole basic region of the protein and its nuclear localization signal (NLS). 
    As a protein-derived cell-penetrating peptide, TAT is able to deliver attached cargoes into many 
cell types shown as below, which make it a promising “bio-carrier” for diagnostic and therapeutic 
applications. TAT uptake by most cells is time- and concentration- dependent, as indicated by reports 
of TAT-mediated cytoplasmic uptake of fusion protein [64-66], plasmid DNA [67-69], nanoparticles [70-74], 
liposomes [75-77], and micelles [78, 79]. This is the main reason why TAT was chosen as the CPP used for 
this thesis work. 
    In 1999 Steven F. Dowdy and coworkers found that the protein transduction domain (PTD) fused 
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to 3-galactosidase protein can be delivered into all tissues in mice, including the brain. [64] Then in 2002 
Guodong Cao and coworkers showed that injecting of a Bcl-xL fusion protein containing TAT protein 
transduction domain into mice decreased cerebral infarction (up to ~ 40%) in a dose-dependent manner. 
[65] In 2003 Steven F. Dowdy showed that fusing the TAT protein transduction domain (PTD) to the 
N-terminus of BCLXL and FNK facilitated the delivery of the proteins into cells and tissues in vivo 
resulting in protection of neuronal cells following ischemic stroke. [66]  
Astriab-Fisher and coworkers used conjugates of antisense oligonucleotides (ODN) with the 
cell-penetrating TAT peptide to target an aberrant splice in a luciferase containing gene resulting in 
splicing correction and an increase in Luciferase activity in a dose-responsive manner in HeLa cells. 
The peptide-oligonucleotide conjugates progressively entered cells over a period of hours and were 
detected in cytoplasmic vesicles and in the nucleus. [67] Shu Yang and coworkers demonstrated that the 
HIV TAT(48-60) protein fragment can be used to construct cationic peptide-DNA complexes that can 
deliver exogenous DNA in vitro along with chloroquine to protect DNA from degradation and enhance 
cytoplasmic delivery of the peptide-DNA complexes. [68]  
Yoshie Maitani and coworkers reported a tetra-arginine conjugated-PEG lipid-coated protamine 
(PD) as a promising gene delivery vector for gene delivery in tumor by intratumoral injection. And 
transfection efficiency in tumors and in vitro greatly depended on the charge ratios of (Arg)n-B to DNA 
and the length of Arg residues. [69] 
    Ralph Weissleder et al conjugated different number of TAT peptides to superparamagnetic iron 
oxide nanoparticles in order to improve their intracellular uptake. They also demonstrated that 
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increasing the numbers of TAT peptides per particle increases the cellular uptake of iron oxide 
nanoparticles in a nonlinear fashion. The increase in sensitivity of the MR imaging agents allowed in 
vivo tracking cells about 100-fold lower cell concentration than currently described. [70] In 2000, they 
designed and made a TAT peptide-derivatized superparamagnetic nanoparticle with a novel triple-label 
(magnetic, fluorescent, isotope) which could be efficiently delivered into hematopoietic and neural 
progenitor cells in vitro at around 10–30 pg of superparamagnetic iron per cell. It was found that single 
cells could be detected by magnetic resonance (MR) imaging in tissue samples in vivo, and that the 
cells could be recovered by magnetic separation columns. [71]  
    Later Karen L. Wooley, John S. Taylor and coworkers compared nanoparticle shape/size effect on 
cellular uptake concerning nanoparticles functionalized with TAT protein peptide, and detected that the 
small spherical nanoparticles had a higher intracellular incorporation rate into CHO (Chinese hamster 
ovary) cells than did those large cylindrical nanoparticles. [72] Other types of nanoparticles like 
biocompatible gold nanoparticles functioned with TAT PTD can transverse the cell membrane of 
human fibroblast cell lines in vitro. In this case, the size of the gold nanoparticles influenced the 
nuclear entry efficacy, with 5 nm particles being able to enter the nucleus while large 30nm particles 
were retained in the cytoplasm. [73] Vinod Labhasetwar and coworkers conjugated TAT peptide to 
nanoparticles in order to increase the transport of the encapsulated ritonavir (a protease inhibitor, PI) 
across the blood-brain-barrier (BBB) into the central nervous system (CNS). Their results showed that 
despite their larger size of ~300 nm (hydrodynamic diameter) which is much larger than the openings 
in the BBB (~8.1 nm), TAT-conjugated NPs were transported across to the parenchyma to maintain a 
therapeutic drug level for around four weeks. [74] 
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Vladimir P. Torchilin [75] and coworkers demonstrated that relatively large size drug carrying 200 
nm liposomes can also be delivered into cells, if the TAT peptide is attached to the liposome surface 
through a spacer or a high MW polyethylene glycol. Otherwise steric hindrance blocks the direct 
contact between the TAT peptide and the cell surface, thereby abolishing intracellular delivery of the 
liposome into the cells. Later this same group [77] showed that not only pNP-PEG-PE 
(p-nitrophenylcarbonyl-PEG-phosphatidylethanolamine) but also pNP-PEG-DOPE 
(p-nitrophenylcarbonyl-PEG-dioleoyl phosphatidylethanolamine) can be delivered into cells by 
attaching TAT peptide to liposomes with covalent bonds respectively, then probably through a 
mechanism of spontaneous formation of certain membrane structures like vesicles or micelles.  
Marjan M. Fretz [76] and coworkers found that coupling TAT peptide to the outer surface of 
liposomes resulted in enhanced endocytosis of the liposomes by ovarian carcinoma cells. Supporting 
evidence that the intracellular delivery mechanism involved endocytosis was provided by the inhibitory 
effect of heparin or dextran sulfate, and confocal microscopy studies showing that binding of the 
TAT-liposomes to the plasma membrane was followed by intracellular uptake in vesicular structures. 
    You Han Bae [78] and coworkers designed and assembled a TAT peptide conjugated micelle 
system which was completed and shielded with a pH-sensitive dib lock copolymer. The TAT micelles 
had particle sizes between 20 and 45 nm, and upon complexation showed particle sizes between 60 and 
90 nm. Flow cytometry and confocal microscopy showed a higher uptake of TAT micelles into the 
cytoplasm and nucleus of the acidic tumors at pH 6.6 than that at pH 7.4, which indicated shielding at 
normal pH and deshielding at tumor pH. In 2009 Rupa R. Sawant and Vladimir P. Torchilin [79] 
attached TAT peptide to the ends of polyethyleneglycol-phosphatidylethanolamine (PEG-PE) micelles 
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containing paclitaxel (PCT) with average sizes of 8-25 nm. Both in vitro and in vivo tests of 
TAT-modified micelles demonstrated an increased interaction with cancer cells compared to micelles 
without TAT, and an increase in cytotoxicity to different cancer cells in vitro. 
In addition to the experimental results discussed above, thermodynamic factors were also 
considered in choosing TAT as the CPP for the thesis work. The theoretical value of Gibbs free 
energies were calculated according to the Wimley-White interfacial scales and hypothesis [59] described 
as before. Then the experimental value of Gibbs free energy was derived from the equation of ∆G=RT 
lnKD. This experimental value can be compared with the theoretical value calculated from the 
Wimley-White interfacial scales, after adding the cratic correction of -2.4 kcal/mol, and the 
electrostatic correction of -4kcal/mol, depending on different CPPs. (Table 1.3) 
Table 1.3 Theoretical and experimental values of Gibbs free energy for TAT peptide insertion into a 
membrane (I) 
TAT : ∆Gif = +2.2 kcal/mol  (theoretical value) 
∆Gexp = RTlnKD–2.4 kcal /mol–4 kcal/mol= –7.4 kcal/mol  (experimental value) 
∆∆G=9.6 kcal/mol 
As shown above, the experimental Gibbs free energy of binding is >9 kcal/mol (∆∆G=9.6 
kcal/mol) more negative than the calculated value. This discrepancy between the theoretical and 
experimental values for TAT is too large to be explained solely by inaccuracies in the parameters. If a 
significant number of intramolecular hydrogen bonds were formed by the peptide, the binding free 
energy might be significantly lower. Using -0.4 kcal/mol for per residue to form intramolecular 
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hydrogen bonds, the maximum total contribution from TAT peptide (11 amino acid residues) alone 
would be -4.4 kcal/mol. If the terminal free COO- group establishes a salt bridge with one of the Arg or 
Lys residues; this could further contribute about - 2 kcal/mol to the binding Gibbs energy. [60] 
Altogether, those hydrogen bonds would bring the value of ∆Gif to -4.2 kcal/ mol, which is closer to the 
-7.4 kcal/mol derived from experiment with ∆∆G = 3.2 kcal/mol. (Table 1.4) 
Table 1.4 Theoretical calculation and Experimental values of Gibbs free energy for TAT peptides (II) 
TAT : ∆Gif = +2.2 kcal/mol–4.4kcal /mol–2kcal/mol=–4.2kcal/mol (theoretical value) 
∆Gexp = RTlnKD–2.4kcal /mol–4kcal/mol=–7.4kcal/mol (experimental value) 
∆∆G = 3.2 kcal/mol 
    All the above information suggests that the large discrepancy in theoretical and experimental 
values for TAT peptide reveal a real difference between the assumed and the actual conformations of 
the TAT peptide on the membrane. Thus, it is highly possible that TAT peptide does not adopt a 
regular secondary structure. Probably additional hydrogen bonds were formed within the peptide 
involving the arginine side chains, which further lowered the free energy upon binding. 
    Although the Wimley-White theoretical estimates of TAT was not very close to the experimental 
determinations of the Gibbs energies of transfer calculation, like those shown before for the α-helical 
peptides of Tp10W and penetratin [60]. Fortunately the experimental value was lower than that from the 
theoretical calculation, which confirms that it should be an effective cell-penetrating peptide for 
intracellular delivery. Thus, this is a second reason for choosing TAT as the CPP used for thesis work. 
Moreover, the continuing synthesis of PNA-peptide conjugates can be easily assembled by Fmoc 
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chemistry on the solid support with TAT peptide, which was provided as the third reason. 
 
1.6 Lipid modification of GRN163 to improve cell-membrane permeability [80] 
    While TAT peptide has been shown to deliver antisense agents into cells, the efficiency has still 
not been that great, and we were interested in seeing if we could further enhance the efficiency by 
attaching a lipophilic molecule.  At the time that we were considering this problem, there were reports 
that attachment of lipids to an antisense telomerase agent greatly improved the bioavailability. 
    Most human cancer cells over-express telomerase, while this is not the case in somatic cells. Since 
inhibition of telomerase has been shown previously to lead to progressive telomere shortening, cell 
growth arrest or cell death due to the critically shortening of telomeres, telomerase became an attractive 
cancer therapeutic target over the past years. Among the several mechanisms, using antisense 
oligonucleotides directly targeting the hTR (human telomerase RNA) template to inhibit telomerase 
activity has shown the potential for application in cancer therapy. However, the major problem in the 
effective and general utilization of oligonucleotides as anti-telomerase cancer drugs is their low ability 
to transverse cell membrane. 
    In order to solve this problem, lipophilic carriers or liposomes as transfection reagents were used 
in vitro to facilitate the intracellular delivery ability of oligonucleotides, but this method cannot be 
applied easily in the clinic. Then, chemical modification of the oligonucleotides became another 
feasible way to improve the intracellular uptake. One successful modification was to replace the 
3’-oxygen of oligonucleotides with 3’-nitrogen to make N3’-P5’ phosphoramidate and 
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thio-phosphoramidates (GRN163 and GRN163L, Figure1.22) as effective telomerase inhibitors. 
Similarly better telomerase inhibition effect of these oligonucleotides was also demonstrated, when the 
transfection reagent were combined with them in the in vitro tests. Like the normal oligonucleotides, 
this needed to be improved before in vivo administration was feasible. Thereafter, a lipid modification 
of oligonucleotide thio-phosphoramidates of GRN163L was designed and tested for the telomerase 
inhibition by Britteney-Shea Herbert and coworkers, who found a greatly enhanced effect compared 
with the former generation of oligonucleotides of GRN163 without a lipid modification. 
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Figure 1.22 Structures of N3’-P5’ phosphoramidate and thio-phosphoramidates (GRN163 and 
GRN163L) by replacing the 3’-oxygen of oligonucleotides with 3’-nitrogen 
This was the first report to show that lipid modification enhanced the potency of the GRN163 
telomerase inhibition, which was testified by in vitro in different cell lines. In the cell-free-based TRAP 
assay, GRN163 was still more potent than the lipid modified GRN163L, with an IC50 value of ~1.4 
compared to ~7.8 nM for GRN163L. In immortal HME50-5E cells, the lipid-modified 
phosphoramidate GRN163L could inhibit telomerase activity much more effectively compared to 
GRN163, with an estimated IC50 value of ~150 nM compared to ~20 μM. Inhibition of telomerase 
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activity by GRN163L was dose dependent, while the dose-dependent inhibition of GRN163 depended 
on the use of a transfection reagent. These facts suggested that conjugation of lipid to GRN163 
improved significantly its cell-membrane permeability to better inhibit the telomerase activity inside 
the cell, without the use of transfection reagents. Similar telomerase inhibition results by GRN163 and 
GRN163L were also demonstrated in other cell lines, like tumorigenic HME50-T breast epithelial cell, 
MDA-MB-231 breast carcinoma cells, PC3 human prostate carcinoma cells, cervical tumor cells, 
glioblastoma tumor cells, hepatoma tumor cells, lung tumor cells, melanoma tumor cells, ovarian tumor 
cells, and prostate tumor cells. Thus the conjugation of a lipid to a PNA-TAT peptide conjugate was 
expected to further increase its bioavailability and was targeted for this Ph. D thesis study. 
 
1.7 Determining accessible sites on native mRNAs for therapeutics by MASL  
    Another concern for the development of effective antisense PNA-based diagnostic and therapeutic 
agents is how best to select a specific sequence on an mRNA of interest to insure the highest binding 
affinity of the PNA. Because RNA molecules are folded, not all sites are equally accessible to an 
antisense agent.  Therefore in order for antisense reagents to bind the target mRNAs stably and 
function smoothly as therapeutic or diagnostic reagents, the accessible binding sites of the 
corresponding mRNA need to be known first. Several experimental methods for mapping accessible 
sites on mRNA have been developed in past years, and ODN sequences identified by these methods 
demonstrated high affinity and selectivity for the corresponding target mRNA in vitro. However, 
because many of these methods utilized RNA substrates produced by in vitro transcription of cDNA 
clones, these methods resulted in nonnative mRNAs which lack the endogenous capping sequence and 
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the poly(A) tail. [81-86] The RNAs produced in this way were also often truncated and contained parts of 
sequences arising from the transcription vector, and therefore may not fold exactly in the same way as 
native mRNAs do, thus leaving doubt about the precision of the accessible sites mapped. 
Target RNA +
5'-CATCAGGATGGAATNNNNNNNNNN-3'
5'-tag-random sequence-3'
Target RNA
5'-tag-random sequence-3'
+ Reverse Transcriptase + dNTP
5'-tag-random sequence-(dN)n3'
PCR amplification of extension products
Sequencing gel analysis for RT-ROL products  
Figure 1.23 RT-ROL method (reverse transcription with the random oligonucleotide libraries) to map 
antisense-accessible sites on mRNA 
    To clear this doubt, a method that could map antisense-accessible sites on full-length native 
mRNA targets directly in the isolated total mRNAs from cell culture was required. In 2001 Allawi and 
coworkers [84] first developed the RT-ROL method (reverse transcription with the random 
oligonucleotide library), method for mapping accessible sites as shown above (Figure1.23). In their 
method, a sequence-randomized library of oligodeoxynucleotides (ODNs) linked to the 3’-end of a 
PCR-tag sequence was used to hybridize to the RNA. The ODNs were extended with reverse 
transcriptase and the extended products were amplified by using the PCR primers from the different 
sites along the target mRNAs. Then the PCR (Polymerase Chain Reaction) products could be aligned 
with specific sequences of the mRNA according to the PAGE (Polyacrylamide Gel Electrophoresis) 
results to deduce the antisense-accessible sites. 
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Isolate Total mRNA
+ 5'-CATCAGGATGGAATNNNNNNNNNX-3'5'-tag-random sequence-X-3'
Target RNA
5'-tag-random sequence-3'
+ Reverse Transcriptase + dNTP
5'-tag-random sequence-(dN)n3'
PCR amplification of extension products
1) PAGE, 
2) phosphor-image
3) Align sequence
Cell Culture
X=A, C, G, T
mRNA antisense accessible site  
Figure 1.24 MASL method (mRNA antisense-accessible sites library) to improve the precision of 
RT-ROL method 
    One problem with the original method was the difficulty to assign the PCR product bands directly 
to a specific site on the mRNA, which resulted from the difficulty in determining the precise size of the 
PCR product. The other problem was that in vitro transcribed RNA was used as a substrate. To 
overcome these problems, a method named MASL (mRNA antisense-accessible sites library) was 
developed recently by Taylor group [87] with the purpose of improving the precision of the originally 
reported method by Allawi et al which also used native mRNA instead of in vitro transcribed mRNA 
(Figure1.24). [84] 
In MASL four separate random primer libraries terminating in either A, C, G, or T are utilized to 
enable the observed PCR products to be aligned with a specific base in the sequence. This method was 
then employed on whole cell mRNA extract so that the mapping was carried out on native mRNA 
transcripts. The MASL accessible site library was then shown to allow high affinity sites to be 
identified that could be used for selecting highly effective antisense therapeutic agents and imaging 
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probes from series of phosphorothioate oligodeoxynucleotides (ODNs), small interfering RNAs 
(siRNAs) and peptide nucleic acids (PNAs). 
 
1.8 Specific aims of this thesis 
    The overall aim of this thesis was to develop diagnostic and therapeutic PNA agents for a variety 
of disease states that showed better cell penetrating and biodistribution properties than previously 
developed PNA agents.  To this end we envisioned combining PNAs with cell penetrating peptides 
and lipids and then testing their properties in vitro and in vivo. 
    Based on previous studies, two well-studied cell penetrating peptides of TAT and Arg9 were 
chosen to facilitate the intracellular delivery of a series of PNAs targeting different RNAs. Also 
considering the dramatic effects of attaching lipids to GRN163, we decided to also investigate adding 
lipid modifications to the N-terminus of the PNA. 
    We also hypothesized that the hydrophobic lipid chain might direct the self-assembly of the 
conjugates in aqueous environment to form different sized micelles depending on the length of the lipid. 
Hopefully, some combination of CPP and lipid would show optimal membrane permeation and 
biodistribution in vivo (Figure1.25).  
Lipid-PNA-Cell Penetrating Peptide (TAT/R9)
Lipid chain and Cell Penetrating Peptide to facilitate intracellulr delivery
Targeting hTR/iNOS mRNA/umr mRNA
 
Figure 1.25 Design of Lipid-PNA-CPP Conjugates to facilitate intracellular delivery 
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    To detect the location of the PNA in vivo, we also needed to add a fluorescent or radioimaging 
label to the PNA constructs.  The TAT(48-58) peptide appears to be ideal for this purpose as it 
contains a tyrosine residual with a phenol side chain that can be conveniently radiolabeled with Br-76 
for PET imaging studies (Positron Emission Tomography) in collaboration with Michael Welch’s 
group in the Medical School. 
    The thesis work is divided into three studies involving lipidated PNA-cell penetrating peptide 
constructs (Figure1.26 and Figure1.27).  The first (Chapter 2) involves the synthesis, characterization 
and study of the in vitro effectiveness of this class of PNAs as a potential therapeutic for telomerase 
inhibition,  The second (Chapter 3) involves the synthesis, characterization and in vivo study of this 
class of PNAs as breast cancer imaging agents. The third (Chapter 4) involves the synthesis, 
characterization and in vitro study of this class of PNAs as lung injury therapeutic and imaging agents. 
Lipid-PNA(50/5/7)-YGRRKRKKRRR(TAT)
Lipid chain and Cell Penetrating Peptide to facilitate intracellulr delivery
In MCF-7 tumor cells targeting unr mRNA
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Figure 1.26 Design of Lipid-PNA-CPP Conjugates as diagnostic agents 
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Figure 1.27 Formal design of PNA conjugates containing one radiolabelling end 
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Chapter 2 
Lipid / Phospholipid-PNA-Peptide Conjugates to Down-Regulate Human Telomerase Activity 
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Abstract 
    Telomerase is a ribonucleoprotein that has been found to maintain the cellular immortality of 
cancer cells. Therefore, much attention has focused on developing inhibitors of telomerase activity. 
Antisense oligonucleotides targeting the RNA component or human telomerase have shown excellent 
anti-telomerase activity in vitro. Herein we have investigated whether or not lipid / 
phospholipid-PNA-R9 / TAT conjugates targeting the hTR can better down-regulated human 
telomerase activity than non-lipidated PNAs. 
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2.1 hTR as a promising target for inhibition of telomerase activity 
    Human telomerase is ribonucleoprotein complex that compensates for the loss of telomeric 
sequences, due to the DNA end replication problem, [1] by adding tandem repeats of d(TTAGGG) to 
telomeres at the ends of chromosomes (Figure 2.1). The essential role of telomerase is to ensure 
chromosome integrity. [2] It is composed of a catalytic protein subunit, the telomerase reverse 
transcriptase component (hTERT), one or more additional proteins, and a 451-base integral RNA 
component of hTR (human Telomerase RNA). The RNA component, hTR, which serves as a template 
for the synthesis of the telomeric repeats, [3] is critical for the telomerase activity in vitro and in vivo. 
template
new strandprimer
telomere length shortening  
Figure 2.1 Telomere shortening in normal cells 
    Telomerase activity has been detected in over 85% of tumors, [4] but not in somatic cells. 
Telomerase activity is activated and expressed in cancer cells but not in most normal somatic cells 
(Figure 2.2). Biochemical and genetic studies have established a relationship between telomere 
maintenance and extended life span of human cells, which is mediated through the expression of the 
catalytic sub-unit of telomerase (hTERT). Because of this, telomerase has attracted much attention as a 
target for anti-cancer therapy. Telomeres are maintained mainly through telomerase, and telomere 
shortening may make tumor cells more sensitive to chemotherapy agents. 
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Telomerase activation
Telomere maintenance
Signaling for continuation of cell cycle
Cellular immortality
Tumorigenesis  
Figure 2.2 A relationship between Telomerase activation and Tumorigenesis 
    Understanding the structure and function of telomerase has led to a number of strategies for the 
development of inhibitors. [5] These include antisense oligonucleotides targeting hTR [6-10] (RNA 
component) or hTERT [11] (reverse transcriptase) mRNA, traditional small molecule reverse 
transcriptase inhibitors and agents able to promote and/or stabilize G-quartet formation in telomere 
DNA. [12, 13] 
    Among these strategies, targeting hTR with antisense oligonucleotides offers several advantages 
for inhibitor development. [14]  First, hTR Watson-Crick basepairs with telomere DNA in order to 
template DNA synthesis, which makes hTR an ideal target for antisense oligonucleotides. Second, the 
design of antisense oligonucleotide-based inhibitors is straightforward, because the 11-base hTR 
sequence in the template region [15] has already been sequenced. (Figure 2.3) Third, the synthesis of 
antisense oligomers and other conjugates is also straightforward. Last, oligonucleotides or other 
conjugates containing mismatched bases can be used for control experiments to demonstrate the 
mechanism of action. 
template 4060
3'- G A A G A G U C A A U C C C A A U C U G U U U U - 5'
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Figure 2.3 Human telomerase RNA (hTR) template region 
2.2 Design and synthesis of lipid/phospholipid-PNA-CPP conjugates 
    The application of PNAs as genetic diagnostic and therapeutic regents is hampered by their low 
solubility in physiological buffers, tendency to form aggregates, and insufficient cellular uptake and 
poor biodistribution due to rapid excretion in vivo. Fortunately, PNA can be easily modified, and one 
can easily attach peptides and other molecules to either end to improve its biophysical and biochemical 
properties. 
    A number of arginine-rich cell-penetrating peptides (CPPs) appear to confer a high level of 
cellular uptake to what they are attached, [16, 17] probably because of the guanidinium headgroups on the 
arginine residues. It has been proposed that the ability to form bidentate hydrogen bonds, characteristic 
of guanidinium groups, may enable it to bind to proteoglycans associated with the plasma membrane, 
[18,19] and this binding may be the first step in transduction. This seems to agree with the kinetic 
analyses, which indicate that oligomers of arginine composed of six of more amino acids cross 
biological membranes very efficiently. Detailed kinetic assays of nonamers of arginine illustrate that R9 
is significantly more effective at crossing biological membranes than the nonapeptides of TAT(49-57). 
[20] 
Structural considering, TAT(48-58, YGRRKRKKRRR) was also an arginine-rich peptide 
containing eleven amino acid residuals as shown below (Table 2.1), and the lysine residue is 
structurally like the arginine residual with a side-chain containing a positive charge at the end. These 
structures of the lysine and the arginine residuals enable TAT peptide to form hydrogen bonds within 
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the peptide and then adopt an irregular secondary structure. This would explain the large discrepancy 
between the theoretical value and the experimental value of the Gibbs free energy for membrane 
insertion, which indicates a difference between the assumed and the actual conformations of the TAT 
peptide on the membrane. [21-23] 
Table 2.1 Theoretical calculation and Experimental values of Gibbs free energy for TAT peptides 
TAT : ∆Gif = +2.2 kcal/mol–4.4kcal/mol–2kcal/mol = –4.2kcal/mol (theoretical value) 
∆Gexp = RTlnKD–2.4kcal/mol–4kcal/mol = –7.4kcal/mol (experimental value) 
∆∆G = 3.2 kcal/mol 
    Later in 2008, Uffe Koppelhus et al [25] demonstrated that the nuclear antisense activity of PNA 
oligomers can be dramatically enhanced by conjugation of PNA to a CatLip domain (cationic peptide 
lipid domain), consisting of polyarginines or TAT peptide and fatty acid. And this enhancement of the 
nuclear antisense activity was facilitated up to 2 orders of magnitude by the improved intracellular 
delivery of CatLip domain, which was higher than that obtained by using the peptide alone (Figure 
2.4). 
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Figure 2.4 Structures of TAT(48-58) and Rn peptides 
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    David Corey’s group [26] used overlapping PNAs to determine that recognition of cytidines 50-52 
within the template region was critical for efficient inhibition. The 13-mer PNA sequence 
TAGGGTTAGACAA showed the best anti-telomerase activity of all 17 PNAs directed to template 
sites within the hTR, followed by five other PNA sequences. PNA conjugates directed to other sites 
within the hTR were poor inhibitors of telomerase holoenzyme.  
     Xuan Yue et al [27] investigated a 13-mer (CAGTTAGGGTTAG) and an 8-mer (TAGGGTTA) 
PNA sequence from those six best inhibitors discovered by David Corey. She found that the longer 
13-mer PNA sequence which was conjugated to Arg9 had a better intracellular delivery effect and a 
better telomerase inhibition bioactivity. 
    A further improvement in antisense agents targeting the telomerase hTR was found by 
Brittney-Shea Herbert [28] and coworkers. They found that lipid-modification of a N3’-P5’ 
thiophosphoramidate oligonucleotide inhibitor GRN163 greatly improved the in vivo effectiveness of 
the inhibitor as GRN163L. 
    Based on these prior results, we reasoned that an improved anti telomerase PNA could be 
designed by adding either a lipid or phospholipid to one end of the optimal 13-mer PNA sequence 
(TAGGGTTAGACAA) and either the TAT peptide or Arg9 to the other end as shown below (Figure 
2.5). To this end, a library of antisense PNA conjugates of PNA-TAT, Lipid-PNA-TAT, Lipid-PNA-R9 
and Phospholipid-PNA-R9 were designed and synthesized by solid phase chemistry as shown below, 
and then studied for their ability to inhibit human telomerase (Figure 2.6). 
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Lipid(Phospholipid)-PNA(Telm)-Cell Penetrating Peptide(R9/TAT)
Lipid(Phospholipid) chain and Cell Penetrating Peptide to facilitate delivery into cells
Targeting hTR for Telomerase Inhibition
 
Figure 2.5 Design of Lipid(Phospholipid)-PNA(Telm)-CPP(R9/TAT) conjugates 
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Figure 2.6 Structures of Pal-P-Telm-R9, P-Telm-R9, Lipid-Telm-R9, Telm-R9, Lipid-Telm-TAT and 
Telm-TAT conjugates 
 
2.3 Experimental Procedures 
Materials and Methods 
    All reactions were performed under an argon or nitrogen atmosphere unless otherwise specified. 
All commercially available materials were used without further purification unless otherwise noted. 
Anhydrous solvents for reactions, such as DMF, DCM, and acetonitrile were either used as obtained 
from Sigma-Aldrich or distilled from an appropriate drying agent. All chemicals and reagents used 
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were of the highest purity available. Acetonitrile, trifluoroacetic acid, m-cresol and reagents for 
automated PNA synthesis were purchased from Aldrich. Fmoc-D-Arg(Pbf)-OH was purchased from 
Novabiochem for solid-phase synthesis of R9 on an Expedite TM 8900 synthesizer. The 11-mer 
Fmoc-protected TAT on resin, Fmoc-YGRRQRKKRRR-PAL-PEG-PS was purchased from GL 
Biochem. Fmoc-PAL-PEG-PS resin for automated PNA synthesis was purchased from Applied 
Biosystems. PNA-R9 conjugates were assembled on an Applied Expedite TM 8900 synthesizer 
(Applied Biosystems). 1H NMR and 31P NMR spectra were recorded on VarianUnityPlus-300. 
Trimethyl phosphate was used as the external reference for 31P NMR. And all PNA conjugates were 
purified by reversed-phase high-performance liquid chromatography (HPLC) on a Beckman System 
Gold instrument equipped with a UV-vis array detector, using a Microsorb-MV 300-5 C-18 column 
(250×4.6mm column, 300A pore size, Varian Inc.). HPLC fractions were collected and concentrated 
under vacuum in a SpeedVac Evaporator (Savant Inc.). UV-vis absorption of all PNA conjugates was 
determined with a Bausch and Lomb Spectronic1001 spectrophotometer and a Varian Cary 100 bio 
UV-vis spectrophotometer. Concentration of all PNA conjugates was determined by the Beer-Lambert 
law using standard extinction coefficients at UV wavelength of maximum absorbance of 260nm to 
calculate both amounts and Partition Ratios. All PNA conjugates were characterized by MALDI-TOF 
on a PerSpective Voyager RP MALDI-TOF mass spectrometer in linear mode using insulin as the 
internal reference, and α-cyano-4-hydroxycinnamic acid (CHCA) as the matrix. Fluorescence spectra 
were measured on a Varian Cary Eclipse fluorescence spectrophotometer to determine CMC (Critical 
Micelle Concentration). Telomerase PCR ELISA kit was purchased from Roche Applied Sciences. 
Syntheses of the Phosphodiester Intermediate (Compound 2) [25] 
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Figure 2.7 Preparation of 3-((4-Methoxyphenyl)diphenylmethylamino)propan-1-ol 
    4-Methoxytriphenylmethyl chloride (Mmt-Cl) (2 g, 6.5 mmol) was dissolved in anhydrous 
pyridine (20 mL), and 1-amino-propanol (6.87 g, 91.5 mmol) was added and stirred at room 
temperature for 3 days. The pyridine was evaporated and EtOAc was added. The organic phase was 
extracted with saturated aqueous NaCl solution (3×100 mL), dried with Na2SO4, filtered, and 
concentrated. The residue was evaporated and purified by column chromatography to afford the 
product 3-((4-methoxyphenyl)diphenylmethylamino) propan-1-ol in 66 % yield. 1H NMR (CDCl3, 300 
MHz). δ 7.2-7.4 (m, 10H), 7.13 (d, 2H), 6.75 (d, 2H), 7.26 (m, 2H), 3.8 (t, 2H), 3.7 (s, 3H), 2.3 (t, 3H), 
1.63 (m, 2H). 
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Figure 2.8 Preparation of Compound 1[26] 
    3-((4-Methoxyphenyl)diphenylmethylamino)propan-1-ol (0.74 g, 2.33 mmol) was dissolved in 
freshly distilled CH2Cl2 (23 mL). N,N-Diisopropylethylamine (1.63 mL, 9.34 mmol) was added, 
followed by 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (1.04 mL, 4.67 mmol). The mixture 
was stirred at room temperature for 8 h before addition of saturated aqueous NH4Cl solution (100 mL). 
The aqueous layer was extracted with EtOAc (3×100 mL). The combined organic extracts were dried 
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with Na2SO4, filtered, and concentrated. The residue was purified by column chromatography with 
(SiO2, EtOAc:Hexane=v/v=1:1, 3% Et3N) to afford product, Compound 1 in 42 % yield. 1H NMR 
(CD2Cl2, 300 MHz), δ 7.15-7.4 (m, 10H), 7.1 (d, 2H), 6.7 (d, 2H), 3.7 (s, 3H), 3.6 (m, 2H), 3.45 (m, 
2H), 2.42 (t, 3H), 2.15 (t, 2H), 1.72 (m, 2H), 1.2 (m, 2H), 1-1.1 (s, 4H). 31P NMR (CD2Cl2, 121.4 MHz) 
δ =+145 ppm 
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Figure 2.9 Preparation of Compound 2[26] 
    Compound 1 (1.303 g, 2.38 mmol) from the previous step was dissolved in freshly distilled 
CH2Cl2 (9 mL) and CH3CN (9 mL). 2,5-Dioxopyrrolidin-1-yl-12-hydroxydodecanoate (0.75 g, 2.38 
mmol) was added, followed by diisopropylammonium tetrazolide (0.41 g, 2.38 mmol). The mixture 
was stirred at room temperature for 12 h before addition of tert-butyl hydroperoxide (5 M, 1.83 mL). 
The reaction was quenched after 2 h with saturated aqueous NaHCO3 solution (100 mL). The aqueous 
layer was extracted with EtOAc (3×100 mL). The combined organic extracts were dried with Na2SO4, 
filtered, and concentrated. The oil was purified by chromatography (SiO2, 50% EtOAc in hexanes) to 
afford Compound 2 (0.75 g, 42%) as pale yellow oil: 1H NMR (CD2Cl2, 300 MHz) δ 7.54 (m, 4H), 
7.42 (m, 2H), 7.36 (m, 4H), 7.26 (m, 2H), 6.87 (m, 2H), 4.26 (m, 2H), 4.14 (m, 2H), 4.06 (m, 2H), 3.85 
(s, 3H), 2.83 (s, 4H), 2.73 (t, J= 6.2 Hz, 2H, CH2CN), 2.65 (t, J= 7.5 Hz, 2H, CH2CONHS), 2.28 (m, 
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2H), 1.93 (m, 2H), 1.78 (m, 4H), 1.35 (m, 14H); 13C NMR (CD2Cl2, 75 MHz) δ 169.6, 169.1, 158.3, 
146.7, 130.0, 128.7, 128.0, 126.5, 117.0, 113.3, 70.6, 68.5, 66.6, 66.5, 62.0, 55.4, 40.0, 31.6, 31.1, 30.5, 
29.7, 29.6, 29.3, 29.0, 25.9, 25.6, 24.9, 19.9; 31P NMR (CD2Cl2, 121.4 MHz) δ= - 0.1ppm. 
Solid-phase Synthesis of Telm-R9 and Telm-TAT conjugates 
Resin Fmoc Deblocking
WASH
WASH
WASH
Fmoc Deblocking
20% Piperidine / DMF
Telm-R9(TAT) on resin
Activating and Coupling / Capping
0.2M HATU, 0.2M Monomer, Base;
5% Ac2O, 6% 2,6-lutidine, DMF
 
Figure 2.10 Solid-phase Synthetic procedures of Lipid/Phospholipid-Telm-CPP(R9/TAT) conjugates 
    Telm-R9 and Telm-TAT conjugates [27] were all prepared by automated standard Fmoc chemistry 
on 2μmol scale following the general synthesis procedure shown in Figure 2.10. Then the resin with 
Telm-R9/TAT conjugate was washed with anhydrous DMF (3×1 mL) and DCM (3×1 mL) 
respectively, dried with nitrogen for cleavage and purification. 
Synthesis of Lipid-Telm-R9 and Lipid-Telm-TAT conjugates 
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Figure 2.11 Solid-phase Synthesis of Lipid-Telm-R9/TAT conjugates 
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    After the Telm-R9/TAT conjugates [28] were synthesized on the resin, the resin was washed and 
dried by the automated standard Fmoc chemistry synthesis procedure. After this, the resin with the 
conjugates was added into an anhydrous DMF solution (100 μL) containing the fatty acid (20 μmol), 
DCC (20 μmol) and DMAP (20 μmol) and shaken overnight at room temperature. The resin with the 
lipid-Telm-R9/TAT conjugate was then washed with anhydrous DMF (3×1 mL) and DCM (3×1 mL) 
respectively, and dried with nitrogen prior to cleavage and purification. 
Synthesis of Pal-P-Telm-R9, P(CN)-Telm-R9 and P-Telm-R9 conjugates [26] 
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Figure 2.12 Solid-phase synthesis of Pal-P-Telm-R9, P(CN)-Telm-R9 and P-Telm-R9 conjugates 
    After Telm-R9 conjugates were synthesized, the resin was washed and dried by the programmed 
steps, and then added to an anhydrous DMF solution containing the phosphodiester intermediate 
Compound 2 (20 μmol), HATU (20 μmol), DIPEA (20 μmol) and 100 μL DMF and shaken 
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overnight at room temperature. The resin was then washed with anhydrous DMF and DCM three times 
respectively, and dried with nitrogen. Then 1% TFA in DCM solution (6×1 mL) was added to remove 
the Mmt group on the N-terminus before washing with 2% DIPEA and DCM three times each to 
remove the residual acid. The resin was then dried and added to an anhydrous DMF solution (100 μL) 
of palmitic acid (20 μmol), DCC (20 μmol), DMAP (20 μmol) and shaken overnight. The resin was 
then washed with anhydrous DMF/ DCM three times respectively, and dried with nitrogen. The resin 
was then added into an anhydrous DMF solution (100 μL) containing pyridine (20 μmol) and triethyl 
amine (20 μmol) and shaken overnight. The resin was washed with anhydrous DMF and DCM three 
times respectively before cleavage and purification to afford Pal-P-TelmR9 and P-TelmR9 conjugates. 
[26] Under the similar condition to repeat this synthesis route without the deblocking step of 
pyridine/triethyl amine, P(CN)-TelmR9 and P-Telm-R9 conjugates [26] were obtained. 
Cleavage, Purification and Characterization of the Telm-CPP conjugates 
 HPLC m-Cresol / TFA Telm-CPP conjugatesTelm-CPP conjugates  
Figure 2.13 Cleavage and Purification of Telm-CPP conjugates 
    After the synthesis of the conjugates on the resin was completed, the resin was incubated in 400 μ
L TFA/m-cresol (4:1) for 3 h [27] to remove the protecting groups. Then the Telm-CPP conjugates were 
precipitated by the addition of 10 volumes of ice-cold diethyl ether. The crude product was collected by 
centrifugation and purified by reverse phase HPLC with a 65-min 1 mL/min linear gradient from 5 to 
70% of buffer B (0.1% TFA in CH3CN) in buffer A (0.1% TFA in dd water). The fractions containing 
the desired Telm-CPP conjugates were evaporated, dissolved in dd water, and characterized with 
MALDI-TOF with 1% CHCA in 1:1 ratio of acetonitrile to 0.1% TFA in dd water. 
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Determination of Critical Micelle Concentration (CMC) [29] 
    Stock solutions of Pal-P-Telm-R9 and Lipid-Telm-R9 conjugates were diluted in water to different 
concentrations. Two buffers, with or without NaCl were made in 2% methanol/water containing 10 μ
M pyrene, 150 mM NaCl, 5 mM Tris•HCl, pH=7 and 10 μM pyrene, 5 mM Tris•HCl, pH=7. Two 
series of samples were made with or without NaCl for each PNA conjugate, by mixing 25 μL buffer 
and 25 μL stock solutions of different concentrations. Fluorescence emission spectra were obtained by 
exciting the pyrene at 300 nm. The ratio of intensity of the first (373 nm) and third (383 nm) emission 
peaks was plotted against PNA concentration to determine the CMC from the breakpoint in a bilinear 
fit to the data. 
Telomerase Activity Assay  
This assay was carried out in Dr. Tej Pandita’s laboratory at the Washington University School of 
Medicine. 
   First, 293 cells were plated at a density of 2×105 per well in a 24-well plate and allowed to adhere 
overnight. Then the medium was removed and the cells were transfected with 1.25 μM, 2.5 μM or 5 
μM PNA-CPP conjugates, respectively. After a 72 h incubation, the medium was again discarded, and 
the cells were washed with cold PBS three times, followed by the addition of 100 μL trypsin solution 
(0.05% Trypsin/EDTA) in each well. The trypsin was then inactivated by the addition of 400 μL 
regular growth medium. Cells were collected by centrifugation at 3000 rpm for 5 min and their 
telomerase activity was analyzed by Telomerase PCR ELISA kit. 
2.4 Results and Discussion 
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Antisense PNA conjugates and controls for targeting hTR template region, like Telm-R9(TAT), 
Lipid-Telm-R9(TAT), P-Telm-R9, P(CN)-Telm-R9 and Phosphorlipid-Telm-R9 conjugates were 
synthesized, purified by HPLC and characterized with MALDI and studied as inhibitors of human 
telomerase activity. As shown below, MALDI (matrix-assisted laser desorption ionization) was used to 
test and affirm the presence of the correct PNA conjugates through comparison with the calculated and 
experimentally determined molecular masses. 
Table 2.2 MALDI for Telm-R9, Ted-Telm-R9, Pal-Telm-R9, Ste-Telm-R9, Pal-P-Telm-R9, P-Telm-R9, 
P(CN)-Telm-R9, Ted-Telm-TAT, Pal-Telm-TAT, Ste-Telm-TAT and Telm-TAT conjugates 
Sample Cal. MW MALDI 
Figure No 
(Appendix) 
Telm-R9 5011 5015 Figure A2.3 
Ted-Telm-R9 (n=12) 5222 5225 Figure A2.9 
Pal-Telm-R9 (n=14) 5250 5251 Figure A2.6 
Ste-Telm-R9 (n=16) 5278 5279 Figure A2.12
Pal-P-Telm-R9 5585 5586 Figure A2.15
P-Telm-R9 5347 5347 Figure A2.18
P(CN)-Telm-R9 5400 5401 Figure A2.21
Ted-Telm-TAT (n=12) 5360 5356 Figure A2.35
Pal-Telm-TAT (n=14) 5388 5389 Figure A2.38
Ste-Telm-TAT (n=16) 5416 5419 Figure A2.41
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Telm-TAT 5149 5149 Figure A2.32
Because the lipidated and phospholipid modified PNA conjugates have hydrophobic tails and 
charged head groups, they are amphiphilic, and it seemed likely that they would form micelles in 
aqueous phase, which might be relevant to their mechanism of uptake by cells through endocytosis or 
membrane fusion. [30] By using a pyrene-based fluorescence assay, the critical micelle concentrations 
(CMC) of four PNA conjugates were determined in two buffers with NaCl or without NaCl. Because 
the positively charged cell penetrating peptide chains would be expected to repel each other in a 
micelle, it was expected that CMC of PNA conjugates would be lower in the presence of salt. This was 
indeed demonstrated by the CMC of 4 μM for the phosholipid-Telm-R9 in the presence of NaCl and 6 
μM in the absence of NaCl, and both are lower than the corresponding CMC values of lapidated PNA 
conjugates in aqueous phase. This trend was also observed by Gang Shen’s CMC results [30] with 
phospholipid PNA conjugate (decreasing from 1.7 to 1.0 μM) and lipid PNA conjugates (decreasing 
from 9.2 to 4.5 μM), which were synthesized and tested by a splice-correction Luciferase assay later. 
However, the CMC’s in NaCl solution were not lower than those in solutions without NaCl, probably 
because the differences between the lengths of lipid chains were too small to be shown statistically 
stable. 
Table 2.3 CMC for Ted-Telm-R9, Pal-Telm-R9, Ste-Telm-R9, Pal-P-Telm-R9 conjugates 
Sample 
CMC  
(w/NaCl μM) 
Figure No 
(Appendix) 
CMC 
(w/o NaCl μM) 
Figure No 
(Appendix) 
Ted-Telm-R9 (n=12) 11 Figure A2.23 12 Figure A2.22 
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concentrations approaching the CMD.  Therefore, more bioactivity tests would need to be conducted 
before any solid conclusion can be drawn. 
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Chapter 3 
Design and Synthesis of Lipid-PNA-Peptide Conjugates as Better Antisense PET Imaging Agents 
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Abstract 
    Positron emission tomography (PET), as noninvasive imaging technique, is a sensitive and 
specific imaging modality used to investigate diseases at the cellular and molecular levels. Of the 
various PET agents that have been developed to image gene expression in small animal models, 
oligonucleotides appear attractive for the development of new tracers with high specificity, considering 
that an ODN with more than 16 bases can target a unique sequence in the whole human genome. 
Herein a library of Lipid-PNA-TAT conjugates targeting the unr mRNA that is overexpressed in 
MCF-7 breast cancer cells were designed and synthesized. The PNAs contained a tyrosine as part of 
the N terminal of TAT(48-60) peptide sequence which could be radiolabeled with Br-76. The lipidated 
PNA conjugates were studied for their potential to image MCF-7 tumors in vivo by biodistribution 
assays. 
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3.1 Bromine-76 Labeled Radiotracers with promising application in Positron emission 
tomography 
    Radiohalogenated organic compounds are commonly used in research and the clinic as 
radiopharmaceutical probes for molecular imaging via positron emission tomography (PET) or internal 
radiotherapy at the cellular level. [1] Compared with radiofluorination, radiobromination has attracted 
more attention for use in imaging slower physical processes, due to the relatively long half-time of 16.2 
hours for Br-76, compared to 110min for F-18. Bromine-labeled compounds have some advantages 
over iodine-labeled compounds, because they are more stable due to a stronger C-Br bond, and because 
free iodide tends to accumulate in the thyroid. [2] 
    Br-76 decays simultaneously by positron emission (57%) and by electron capture (43%), [3] 
making such agents capable of both PET imaging and radiation therapy. The Br-76 nuclide can be 
conveniently produced via the 76Se(p,n)76Br reaction on most medical cyclotrons. [4] 
With a half-life of 16.2 h, a Br-76-labelled tracer lives long enough to allow target-tissue-selective 
distribution, but sufficiently short so that the bulk of the dose can be delivered to the tissue prior to 
metabolism and elimination of the radiopharmaceutical. Organic compounds can be readily labeled 
with high specific activity (SA), which is a general requirement for the design and the development of 
Br-76-labelled tracers with high target-specificity activity. [5, 6] 
Biological molecules often contain aromatic rings onto which Br-76 can be conveniently 
introduced by using very high specific activity [Br-76] bromide ion in the presence of an oxidant. 
Considering that oligodeoxynucleotides (ODN) with more than 16 bases can target unique sequences in 
 67 
 
the whole human genome [7], there is the opportunity that ODNs labeled with [Br-76] radionuclides 
could become promising as new radiotracers with high specificity for PET imaging and therapeutic 
applications. 
 
3.2 Design and Synthesis of Lipid-PNA-CPP conjugates 
    Unfortunately, naturally occurring ODNs cannot be directly used as nuclear imaging probes 
because they are rapid degraded in vivo by endo- and exonucleases. In addition, ODNs cause 
degradation of target mRNA by RNAse H. In order to increase the in vivo stability of ODNs without 
significantly influencing their biophysical and targeting properties, chemical modifications of the 
sugar-phosphate backbone are required, which increases the difficulty and complexity in the 
preparation steps of the radiotracers, compared with relatively easily-obtained PNAs through 
solid-phase synthesis procedure. 
    To function usefully as a biological radioprobe, antisense PNAs must target a uniquely 
overexpressed mRNA in the tumor cells. Previously the Taylor group discovered from a search of 
NCBI SAGE (serial analysis of gene expression) database that the unr mRNA is approximately 7 times 
more highly expressed in the MCF-7 breast cancer cell line than it is in any normal tissue cell line, and 
that it is present in about 5,000 copies per cell, making it an ideal initial target for imaging studies. By 
using a RT-ROL method for mapping antisense binding sites on native mRNA, three antisense PNAs 
were identified with high binding affinity for the unr mRNA. 
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    The Taylor group then showed that these PNAs with four lysines at the C terminus and a DOTA 
moiety at the N terminus were able to image MCF-7 tumors in mice by PET (Figure1.39 and 
Figure1.40). Though these PNAs showed sequence selective uptake by the tumor, they were rapidly 
excreted and showed little tumor uptake. Herein we designed and synthesized a library of lipidated 
antisense PNA(50/5/7)-TAT conjugates that were expected to be better retained and show higher tumor 
uptake.  The PNA conjugates were synthesized by Fmoc chemistry on solid support, characterized, 
and evaluated as potential imaging probes for MCF-7 tumors in vivo (Figure 3.1 and Figure 3.2). 
Lipid-PNA(50/5/7)-Cell Penetrating Peptide(TAT)
Lipid chain and Cell Penetrating Peptide to facilitate delivery into cells
Targeting unr mRNA in MCF-7 tumor cells
 
Figure 3.1 Design of Lipid-PNA(50/5/7)-TAT conjugates 
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Figure 3.2 Structures of Lipid-PNA(50/5/7)-TAT and PNA(50/5/7)-TAT conjugates 
 
3.3 Experimental Procedures 
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Materials and Methods 
    All reactions were performed under an argon or nitrogen atmosphere unless otherwise specified. 
All commercially available materials were used without further purification unless otherwise noted. 
Anhydrous solvents for reactions, such as DMF, DCM, and acetonitrile were either used as obtained 
from Sigma-Aldrich or distilled from an appropriate drying agent. All chemicals and reagents used 
were of the highest purity available. Acetonitrile, trifluoroacetic acid, m-cresol and reagents for 
automated PNA synthesis were purchased from Aldrich. The 11-mer Fmoc-protected TAT on resin for 
solid-phase synthesis (Fmoc-YGRRQRKKRRR-PAL-PEG-PS) was purchased from GL Biochem. 
Fmoc-PAL-PEG-PS resin for automated PNA synthesis was purchased from Applied Biosystems. 
PNA(50/5/7)-TAT conjugates were assembled on an ExpediteTM 8900 Nucleic Acid Synthesis System 
purchased by Applied Biosystems. And all PNA conjugates were purified by reversed-phase 
high-performance liquid chromatography (HPLC) on a Beckman System Gold instrument equipped 
with a UV-vis array detector, using a Microsorb-MV300-5 C-18 column (250 × 4.6mm column, 300 
Ǻ pore size, Varian Inc.). HPLC fractions were collected and concentrated under vacuum in a 
SpeedVac evaporator (Savant). UV-vis absorption of all PNA conjugates was determined with a 
Bausch and Lomb Spectronic1001 spectrophotometer or a Varian Cary 100 bio UV-vis 
spectrophotometer. The concentration of PNA conjugates were determined by the Beer-Lambert law 
using standard extinction coefficients for the PNA bases at 260nm. All PNA conjugates were 
characterized by MALDI-TOF on a PerSpective Voyager RP MALDI-TOF mass spectrometer in linear 
mode using insulin as the internal reference. A-cyano-4-hydroxycinnamic acid (CHCA) was used as 
the matrix. Fluorescence spectra were measured on a Varian Cary Eclipse fluorescence 
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spectrophotometer to determine CMC (critical micelle concentration). DLS data were obtained in dd 
water on Zetasizer Nano ZS using disposable Low Volume Cells purchased from Malvern Instruments 
Inc. Br-76 was produced at the Washington University cyclotron facility by the 76Se(p,n)76Br nuclear 
reaction on a 76Se-enriched Cu2Se target. 76Br was recovered via a dry distillation method. The 
radionuclide was in the form of [76Br]NH4Br in 0.6 M NH4OH. The solution was filtered through a 
C-18 Sep-Pak light cartridge (Waters Corp.) and blown down to dryness under very mild N2 flow at 
130 °C. High-performance liquid chromatography (HPLC, Dionex, Sunnyvale, CA, USA) was 
performed with an ultraviolet detector operating at 231 nm and a radioactive detector. Agilent Zorbax 
SB-C18 250 × 4.6 mm 5 μm analytical column and Agilent Zorbax SC-C18 250 × 9.4 mm 5 μm 
semi-preparative column were used for analysis and preparative purification, respectively. Acetonitrile 
and water were used as the HPLC mobile phase. RadioTLC was performed using a Bioscan System 
2000 imaging scanner (Bioscan, Washington, DC, USA). All animal experiments were conducted in 
compliance with the Guidelines for the Care and Use of Research Animals published by the Animal 
Studies Committee of Washington University in St. Louis, School of Medicine. 
Synthesis of PNA(50/5/7)-TAT conjugates 
Resin Fmoc deblock
WASH
WASH
WASH
Fmoc Deblocking
20% Piperidine / DMF
PNA(50/5/7)-TAT
Activating and Coupling / Capping
0.2M HATU, 0.2M Monomer, Base;
5% Ac2O, 6% 2,6-lutidine, DMF
 
Figure 3.3 Solid-phase synthetic procedure for the synthesis of PNA(50/5/7)-TAT conjugates 
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PNA(50/5/7)-TAT conjugates[8] were prepared by automated standard Fmoc chemistry procedures 
on a 2 μmol scale after TAT was synthesized on resin by a company. The resin with 
PNA(50/5/7)-TAT conjugates was washed with anhydrous DMF (3 × 1 mL) and DCM (3 × 1 mL) 
respectively, dried with nitrogen for cleavage and purification. 
 
Synthesis of Lipid-PNA(50/5/7)-TAT conjugates 
OH
O
TAT-PNA (50/5/7)
 HPLC
 m-Cresol / TFA
n
+  DCC/DMAP, DMF
O
N
H
PNA(50/5/7) -TAT
n
n=10,12,14,16
Lipid-PNA(50/5/7)-TAT
 
Figure 3.4 Solid-phase Synthesis of Lipid-PNA(50/5/7)-TAT conjugates 
    After the PNA(50/5/7)-TAT conjugates[9] were prepared on the resin, the resin was washed and 
dried by automated standard steps and then added into an anhydrous DMF solution (100 μL) 
containing the fatty acid (20 μmol), DCC (20 μmol) and DMAP (20 μmol) and shaken overnight at 
room temperature. The resin with Lipid-PNA-R9(TAT) conjugates was washed with anhydrous DMF 
(3 × 1 mL) and DCM (3 × 1 mL) respectively, dried with nitrogen for cleavage and purification. 
Cleavage, Purification and Characterization of PNA(50/5/7) conjugates 
 HPLC m-Cresol / TFA
PNA(50/5/7) conjugatesPNA(50/5/7) conjugates  
Figure 3.5 Cleavage and purification of PNA(50/5/7) conjugates 
After the automated synthesis and post-synthetic modification in vials, the resin was incubated in 
400 μL TFA/m-cresol (4:1) [20] for 3 h. The released PNA(50/5/7)-TAT conjugates were then 
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precipitated by the addition of 10 volumes of ice-cold diethyl ether. The crude product was collected by 
centrifugation and purified by reverse phase HPLC with a 65 -min 1 mL/min linear gradient of 5 to 70% 
buffer B (0.1% TFA in CH3CN) in buffer A (0.1%TFA in dd water). The fractions containing the 
desired PNA conjugates were evaporated, dissolved in dd water, and characterized by MALDI-TOF 
with a matrix prepared from 1% CHCA in 1:1 ratio of acetonitrile vs 0.1% TFA in dd water. 
 
Determination of Critical Micelle Concentration (CMC) [10] 
    Stock solutions of Lipid-PNA(50/5/7)-TAT conjugates were diluted in water to different 
concentrations. Two buffers, with or without NaCl in 2% methanol/water as (10 μM pyrene, 150 mM 
NaCl, 5 mM Tris, pH=7) and (10 μM pyrene, 5mM Tris, pH=7). Two series of CMC samples were 
made with or without NaCl for each PNA conjugate, by mixing 25 μL buffer and 25 μL of stock 
solutions of different concentrations. Fluorescence emission spectra were obtained by exciting the 
pyrene at 300 nm. The ratio of intensity of the first (373 nm) and third (383 nm) emission peaks was 
plotted against PNA concentration to determine the CMC from the breakpoint in a bilinear fit to the 
data. 
Dynamic Light Scattering (DLS) Analysis [11] 
    Stock solutions of Lipid-PNA(50/5/7)-TAT conjugates were diluted in water to different 
concentrations. Dynamic light scattering data was used to calculate the average micelle size at different 
concentrations on a Malvern Nano ZS. The average micelle size was plotted against PNA concentration 
to determine the minimum average micelle size range. 
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Determination of Partition Ratios [12] 
    Equal volumes (10mL) of octanol and water were mixed completely and allowed to separate into 
two clear layers. Lipid-PNA(50/5/7)-TAT conjugates were then dissolved in equal volumes (0.15mL) 
of the two clear layers for each sample. The solution was vortexed to allow complete mixing before 
measuring the concentration of the solute in each solvent by UV-vis spectroscopy at 260 nm. The 
partition ratio was calculated as the ratio of the absorption in water vs the absorption in 1-octanol. 
[Br-76] Radiolabeled PNA conjugates (Carried out by Yongjian Liu in Dr. Michael Welch’s 
laboratory at School of Medicine) 
    The radiolabeling of Br-76 for Pal-PNA50-TAT, Pal-PNA50S-TAT, PNA50-TAT and 
PNA50S-TAT conjugates was done with bromoperoxidase (BPO) and hydrogen peroxide at room 
temperature for 1 h in an aqueous phase. Then each radiolabeling reaction solution was purified by 
TLC and HPLC to obtain the Br-76 radiolabeled PNA conjugates with the yield of more than 90%. 
During the HPLC purification step, both the UV-vis detector for PNA-peptide and the radioactivity 
detector for Br-76 were simultaneously monitored to ensure that the fractions collected by HPLC were 
the desired Br-76 radiolabeled PNA conjugates. The concentrations of the purified Br-76 radiolabeling 
PNA conjugates were given in Table 3.1. As for the TLC and HPLC data, see the Attached Data 
Sheet at the end of Chapter 3 for detail as evidence. 
Biodistribution Assay (Carried out by Yongjian Liu in Dr. Michael Welch’s laboratory at School of 
Medicine) 
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    Four HPLC-purified PNA conjugates at a specific activity of 10 μCi/100 μL were injected via 
the tail vein into female nu/nu mice (a group of 15) with MCF-7(IL) tumors and estrogen pellets. The 
biodistribution of the radioactivity in % ID/gram for eight different organs and tumors were collected 
and averaged for 5 mice for three time points of 1 h, 4 h and 24 h after injection. 
3.4 Results and Discussion 
Eleven antisense Lipid-PNA-TAT conjugates and three controls were synthesized and 
characterized by MALDI, CMC, DLS and partition ratio. As shown below, MALDI (matrix-assisted 
laser desorption ionization) was used to test and confirm the presence of the correct PNA conjugates in 
a specific HPLC fraction. 
Table 3.1 Sequences of PNA-TAT used as PNA50-TAT, PNA50S-TAT, PNA5-TAT and PNA7-TAT 
Sample Sequence 
PNA50-TAT TGGTGTGCTTTGTGGATG-YGRKKRRQRRR 
PNA50S-TAT CATCCACAAAGCACACCA-YGRKKRRQRRR
PNA5-TAT CATTATGTCCATTGTTGT-YGRKKRRQRRR 
PNA7-TAT TTTCCCAGTCCGTCGGTC-YGRKKRRQRRR 
 
Table 3.2 MALDI for Lipid-PNA(50/5/7)-TAT and PNA(50/5/7)-TAT conjugates 
Sample Cal MW MALDI 
Figure No 
(Appendix) 
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Ste-PNA50-TAT 6810 6828.5 Figure A3.18 
Pal-PNA50-TAT 6782 6784 Figure A3.9 
Ted-PNA50-TAT 6754 6764.58 Figure A3.15 
Lau-PNA50-TAT 6726 6741.32 Figure A3.12 
PNA50-TAT 6544 6548.6 Figure A3.3 
PNA50S-TAT 6327 6329.7 Figure A3.6 
Ste-PNA5-TAT 6673 6688.64 Figure A3.33 
Pal-PNA5-TAT 6407 6658.38 Figure A3.30 
Ted-PNA5-TAT 6617 6629.43 Figure A3.27 
Lau-PNA5-TAT 6589 6599.28 Figure A3.24 
PNA5-TAT 6407 6407 Figure A3.21 
Ste-PNA7-TAT 6620 6628.59 Figure A3.45 
Pal-PNA7-TAT 6592 6603.12 Figure A3.42 
Ted-PNA7-TAT 6564 6573.29 Figure A3.39 
PNA7-TAT 6354 6350.4 Figure A3.36 
By using a pyrene-based fluorescence assay, the critical micelle concentrations (CMC) of the 
eleven Lipid-PNA-TAT conjugates were determined in two aqueous buffers of with NaCl or without 
NaCl. The CMC values of almost all Lipid-PNA-TAT conjugates in the aqueous buffer with NaCl 
were lower than those CMC values of corresponding Lipid-PNA-TAT conjugates in the aqueous buffer 
without NaCl, except for Lau-PNA50-TAT. This trend was also found by Gang Shen [14] for 
Lipid-PNA-R9 conjugates, utilizing a Luciferase splice-correction PNA sequence. The similarity was 
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probably because the TAT group containing six arginine residues along with two lysine residues 
thereby having a similar positive charge repelling each other in a micelle or a vesicle formed. 
Considering the different lengths of the lipid chains used in those lipid-PNA-TAT conjugates, no 
apparent relation or trend was found between the length of the lipid chains and the CMC values, 
probably because the differences between the lengths of lipid chains were too small to be shown any 
detectable differences in CMC, or because the pyrene based CMC method used was not sensitive or 
accurate enough to detect subtle differences. 
Table 3.3 CMC for Lipid-PNA(50/5/7)-TAT conjugates 
Sample 
CMC 
(w/NaCl μM) 
Figure No 
(Appendix) 
CMC  
(w/o NaCl μM) 
Figure No 
(Appendix) 
Ste-PNA50-TAT 9.4 Figure A3.64 15.5 Figure A3.63 
Pal-PNA50-TAT 9 Figure A3.62 14 Figure A3.61 
Ted-PNA50-TAT 10 Figure A3.60 14 Figure A3.59 
Lau-PNA50-TAT 12.4 Figure A3.58 11.7 Figure A3.57 
Ste-PNA5-TAT 15.5 Figure A3.72 18.8 Figure A3.71 
Pal-PNA5-TAT 7.8 Figure A3.70 23.4 Figure A3.69 
Ted-PNA5-TAT 10 Figure A3.68 18.8 Figure A3.67 
Lau-PNA5-TAT 14.1 Figure A3.66 15.6 Figure A3.65 
Ste-PNA7-TAT 13 Figure A3.78 20.8 Figure A3.77 
Pal-PNA7-TAT 20.7 Figure A3.76 26.1 Figure A3.75 
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Ted-PNA7-TAT 7.5 Figure A3.74 12.5 Figure A3.73 
Because these Lipid-PNA-TAT conjugates contained hydrophobic tails and hydrophilic 
PNA-TAT parts, it was likely that those amphiphilic conjugates would form micelles in aqueous phase, 
which might explain their better uptake into cells through endocytosis or membrane fusion [30]. 
However, from the DLS results, the vesicle sizes formed from Lipid-PNA-TAT conjugates in the 
aqueous phase was found to be in the range of 90-260nm. This size range falls into the category of 
large size vesicles with spherical shape, which may be optimal for macropinocytosis, instead of 
micelle-induced intracellular delivery. And the relatively large vesicles size formed from those 
Lipid-PNA-TAT conjugates in the aqueous phase was probably due to the lack of the strong 
electrostatic repulsion at the ends of the PNAs, while PNA and lipid chain were neutral. 
Table 3.4 DLS for Lipid-PNA(50/5/7)-TAT conjugates 
Sample DLS (nm) 
Figure No 
(Appendix) 
Ste-PNA50-TAT 290.2 Figure A3.49
Pal-PNA50-TAT 222.2 Figure A3.48
Ted-PNA50-TAT 303.9 Figure A3.47
Lau-PNA50-TAT 247.4 Figure A3.46
Ste-PNA5-TAT 210.8 Figure A3.53
Pal-PNA5-TAT 185.6 Figure A3.52
Ted-PNA5-TAT 94.7 Figure A3.51
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Lau-PNA5-TAT 108.4 Figure A3.50
Ste-PNA7-TAT 184.9 Figure A3.56
Pal-PNA7-TAT 204 Figure A3.55
Ted-PNA7-TAT 260.1 Figure A3.54
    The water/octanol partition ratios results of the Lipid-PNA-TAT conjugates showed that most of 
the Lipid-PNA-TAT conjugates greatly preferred the aqueous phase instead of the organic octanol 
phase. These results are in accord with the formation of micelles in which the positively charged 
peptide ends are exposed to water, while the hydrophobic lipid tails are buried within the core of the 
micelle. 
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Table 3.5 Partition Ratio for Lipid-PNA(50/5/7)-TAT conjugates 
Sample 
Partition Ratio  
(dd water/octanol) 
Ste-PNA50-TAT 232 
Pal-PNA50-TAT 258.5 
Ted-PNA50-TAT 241.2 
Lau-PNA50-TAT 612.6 
Ste-PNA5-TAT 245.2 
Pal-PNA5-TAT 347.2 
Ted-PNA5-TAT 244.98 
Lau-PNA5-TAT 464.4 
Ste-PNA7-TAT 158.9 
Pal-PNA7-TAT 258.4 
Ted-PNA7-TAT 175.8 
Since the purpose of designing and synthesizing the lipid-PNA-TAT conjugates was to test their 
application as potential radioactive imaging agents for PET, Pal-PNA50-TAT and Pal-PNA50S-TAT 
conjugates were radiolabeled by Br-76 with bromoperoxidase (BPO) and hydrogen peroxide and 
purified by TLC and HPLC. The bromine-76 radiolabeling yield was calculated to be more than 90% 
from analysis of the UV-vis and radioactivity HPLC detection data, which indicated that the reaction 
for radiolabelling with Br-76 was very successful (Table 3.1). 
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Table 3.6 [Br-76] Radiolabeling yield of PNA conjugates 
Figure 3.6 Biodistribution (% ID/gram) of Pal-PNA50-TAT and Pal-PNA50S-TAT conjugates 
Table 3.7 Biodistribution of Pal-PNA50-TAT and Pal-PNA50S-TAT conjugates in %ID/gram 
%ID/gram 1 h Pal-PNA50-TAT 1 h Pal-PNA50S-TAT 4 h Pal-PNA50-TAT 
blood 2.0+/‐0.4  1.2+/‐0.3  2.21+/‐0.27 
lung 36.0+/‐8.7  13.7+/‐1.0  43.1+/‐11.9 
liver(all) 96+/‐16  66.6+/‐7  89.7+/‐11.7 
spleen 16.0+/‐4.2  10.3+/‐0.5  16.8+/‐4.7 
kidney 12.00+/‐0.62  6.7+/‐0.7  22.1+/‐5.2 
muscle 0.84+/‐0.13  0.56+/‐0.08  1.09+/‐0.27 
heart 3.7+/‐0.90  2.15+/‐0.33  3.81+/‐0.55 
0.0000
10.0000
20.0000
30.0000
40.0000
50.0000
60.0000
70.0000
80.0000
90.0000
100.0000
%ID/gramSample mCi/μmol 
Pal-PNA50-TAT 140 
Pal-PNA50S-TAT 160 
PNA50-TAT 53.5 
PNA50S-TAT 52.8 
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brain 0.185+/‐0.050  0.12+/‐0.02  0.291+/‐0.056 
tumor 1.39+/‐0.28  1.14+/‐0.28  2.03+/‐0.33 
%ID/gram 24h Pal-PNA50-TAT 24h Pal-PNA50S-TAT 4 h Pal-PNA50S-TAT 
blood 1.16+/‐0.03  2.29+/‐0.36  1.91+/‐0.14 
lung 16.1+/‐3.0  10.3+/‐1.3  9.1+/‐1.4 
liver(all) 55+/‐11  49+/‐18  84+/‐5 
spleen 11.3+/‐1.9  9.5+/‐4.0  13.1+/‐0.9 
kidney 16.0+/‐1.0  8.3+/‐2.8  8.4+/‐1.2 
muscle 0.71+/‐0.07  0.97+/‐0.15  0.62+/‐0.07 
heart 2.35+/‐0.59  2.10+/‐0.31  2.00+/‐0.34 
brain 0.27+/‐0.04  0.51+/‐0.03  0.200+/‐0.014 
tumor 1.78+/‐0.43  1.9+/‐0.3  1.43+/‐0.13 
    The Pal-PNA50-TAT and Pal-PNA50S-TAT conjugates were injected into female nu/nu mice to 
test their biodistribution in vivo. Considering the biodistribution data of % ID/gram in the organs and 
tumors collected, the sense sequence of Pal-PNA50S-TAT conjugate showed apparently higher % 
ID/gram values than those of the antisense sequence of Pal-PNA50-TAT conjugate.  
    And when the biodistribution values of % ID/gram were considered, the highest % ID/gram value 
was found in liver, followed by those moderate % ID/gram values in lung, spleen and kidney, and even 
lower % ID/gram values in other four organs, while in tumor only 1-2 % ID/gram was obtained. 
However, as far as the biodistribution data in tumor were concerned, more experiments need to be 
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conducted before any solid conclusions can be drawn since the % ID/gram values were too low to be 
used. 
    Compared with the previous biodistribution results of Cu64-DOTA-Y-PNA50-K4 conjugates by 
Xiankai Sun [13] and coworkers, this bromine-radiolabeling Pal-PNA50-TAT conjugates 
(Pal-PNA50-(Br-76)TAT) showed that lipidation results in better and longer blood retention of up to  
1.8 % ID/gram at 24 hours. There was also much less loss through the kidneys. 
    The biodistribution data clearly illustrated that the tumor-specificity of Pal-PNA50-TAT 
conjugate still needs to be improved if one hopes to be able to better image the tumor. The lack of 
sequence-specificity of tumor uptake was probably due to the self-blocking effect in vivo which 
induced lower tumor-specific targeting of Pal-PNA50-TAT, which was also shown similarly in Xiankai 
Sun’s result. [13] Because applied as a radiolabelled agent being delivered to the targeting tumor, not all 
the Pal-PNA50-TAT molecules bear the radioactive Br-76 at that moment, then those radio-inactive 
agents tend to also target the tumor as self-blocking agents without radio-imaging activity. To improve 
the intracellular uptake of the PNA conjugates into tumors, may require screening a variety of lipid and 
cell penetrating peptide combinations, including phospholipids [14] and perhaps perfluorinated lipids [15], 
in an effort to reduce the size of the micelles to allow higher intracellular uptake through endocytosis. 
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Chapter 4 
Design and Synthesis of Lipid-PNA-Peptide Conjugates as mRNA accessible Reagents for 
inhibiting iNOS Activity in Acute Lung Injury 
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Abstract 
    Nitric oxide synthase (NOS) has been shown to be overexpressed in acute lung injury and a 
number of human tumors compared to normal tissues and therefore potentially represents a potential 
target in future anticancer therapies. Due to lack of exact gene transcription mechanism of iNOS in 
tumor cells, effort was put into development of method (mRNA antisense-accessible sites library 
[MASL]) to generate rapidly a library of antisense-accessible sites on native mRNAs. Then a library of 
antisense lipid-PNA-TAT conjugates was obtained through solid-phase synthesis, in order for studying 
the effectiveness of inhibiting the activity of iNOS induction via Griess assay in vitro. 
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4.1 Nitric Oxide Synthase (NOS) and mechanisms of iNOS induction in human cells 
    Nitric oxide synthase (NOS) is a dimeric enzyme that consists of two identical monomers: a 
reductase domain with sharing a high degree of sequence homology with P450 reductase, [1] and a 
heme containing oxygenase domain responsible for the production of nitric oxide. [2, 3] The reductive 
domain supplies reducing equivalents to the oxygenase domain, where nitric oxide is produced by a 
two-step oxidation of L-arginine to L-citrulline in the presence of oxygen.[3]  
    Three distinct isoforms of the enzyme nitric oxide synthase (NOS) have been found encoded by 
three different genes: endothelial, neuronal and inducible NOS genes. [4] The three isoforms differ in 
both structure and function [5] but share about 50% sequence homology [6] with distinct catalytic 
activity for each isoform. The endothelial and neuronal types (eNOS and nNOS) are constitutive and 
calcium/calmodulin dependent, and are regulated primarily by calcium influx and generate low levels 
of nitric oxide for short periods of time. The inducible NOS type (iNOS) is not dependent upon 
calcium/calmodulin for enzymatic action, and is induced by cytokines in almost every cell type. 
Inducible NOS can locally generate high concentrations of NO for prolonged periods of time. 
    In human cells iNOS is induced in response to cell injury and maximal induction of the iNOS 
gene occurs in the presence of two signals: IFNc and other stimulus such as an endotoxin. The stimulus 
binds to a κB element in the iNOS promoter [7] to activate the transcription factor NF-κB (nuclear 
factor-κB), and IFNc binds to elements in the NOS promoter to activate the transcription factor IRF-1 
(interferon regulatory factor-1). [8, 9] Then synergism between NF-κB and IRF-1 is believed to be 
achieved through the interaction between these two transcription factors while binding to the iNOS 
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promoter, which leads to modifications in the physical structure of the iNOS 5’ flanking region. [7] This 
is a general description of iNOS pathway in most human cells where NO-mediated cytotoxicity is 
essential in fighting infection, even if the exact mechanisms in specific cell types need further 
examinations. 
    As far as iNOS induced lung infection and inflammation is concerned, although NO· is produced 
by several isoforms enzyme of NO synthase, the increased production of NO· is primarily due to 
induction of type 2 NOS enzyme (iNOS2) in various cell types. [10] According to experiments in normal 
wild type cells and in type 2 nitric oxide synthase-deficient (iNOS2-/-) mice, almost all the biomarkers 
concerning lung injury and NO production were less pronounced in iNOS2-deficent (iNOS2-/-) mice 
than in wild-type mice. 
    The exact mechanism by which iNOS2 is induced in acute lung inflammation and injury is 
incompletely understood. It was suggested that iNOS2 participates in the acute inflammatory response 
to (LPS) lipopolysaccharide by multiple mechanisms: involvement in proinflammatory cytokine 
signaling and alteration of the expression of various genes that affect inflammatory-immune responses 
to LPS. [11] 
The mechanism of iNOS2 in airway inflammation and injury has been proposed to be initiated by 
the formation of reactive nitrogen species (RNS) that induce oxidative injury to host cells and promote 
inflammation. RNS appeared to specifically regulate cytokine signaling in various mononuclear cells, 
appeared to be involved in allergic airway inflammation by selectively downregulating IFNγ-activity, 
[12] and appeared to participate in proinflammatory cytokine signaling by activating the transcription 
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factor nuclear factor (NF-κB) in hemorrhagic shock. [13] These observations would implicate NO· in 
early stages of the inflammatory response was preceding the formation of RNS, and was responsible 
for the activation and regulation of NF-κB (the transcription factor), a key event in the initiation of 
inflammation. [14] However, studies of this key event uncovered both stimulatory and inhibitory effects 
of NO·, which involved several signaling proteins. Thus it was most possible that the different types of 
effects of NO· on NF-κB signaling depend on cell type, the relative NO· concentration, and/or the 
stages of the inflammatory response. [15-19] 
 
4.2 Design and Synthesis of Lipid-PNA-CPP conjugates as iNOS-mRNA as possible diagnostic 
and therapeutic reagents 
    As discussed above, the exact mechanism of this iNOS2 induction responsible for NO production 
in acute lung inflammation and injury still remains unclear on molecular level. However, iNOS2 
deficiency corresponds to an attenuated inflammatory response and reduced injury in various models of 
airway inflammation, [20-26] as demonstrated in animal experiments using wild-type and iNOS knockout 
mice. Thus it would appear that agents capable of imaging iNOS induction and suppressing iNOS 
induction could be useful as diagnostic and therapeutic agents for lung injury. 
    One possible approach to developing diagnostic and therapeutic agents targeting iNOS would be 
to use antisense PNA conjugates that have high affinity for iNOS mRNA. Under this condition 
possibility to design iNOS inhibition reagents still leaves open, should the knowledge of 
antisense-accessible sites on native iNOS mRNAs be available. And as discussed in the introduction, a 
 90 
 
method called MASL (mRNA antisense-accessible sites library) was developed recently by Taylor 
group [27] based on the original reported method by Allawi and coworkers.[28] A number of 
antisense-accessible sites were identified by MASL on native iNOS mRNA extracted from cells, that 
were shown to have high binding affinity and able to inhibit iNOS expression.  
    Herein we describe the design, synthesis and characterization of a library of antisense 
Lipid-PNA(480/240)-TAT conjugates (Figure 4.2). These conjugates were evaluated for their potential 
as both antisense therapeutic agents and diagnostic imaging agents for iNOS. 
Lipid-PNA(240/480)-Cell Penetrating Peptide(TAT)
Lipid chain and Cell Penetrating Peptide to facilitate delivery into cells
Targeting iNOS mRNA to inhibit Activity of inducible Nitric Oxide Synthase
 
Figure 4.1 Design of Lipid-PNA(240/480)-TAT conjugates 
Lipid-PNA(480/240)-TAT
PNA(480/240)-TAT
O
N
H
PNA(480/240)-TAT
n
n=10,12,14,16
PNA(480/240)-TAT  
Figure 4.2 Structures of Lipid-PNA(480/240)-TAT and PNA(480/240)-TAT conjugates 
 
4.3 Experimental Procedures 
Materials and Methods 
    All reactions were performed under an argon or nitrogen atmosphere unless otherwise specified. 
All commercially available materials were used without further purification unless otherwise noted. 
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Anhydrous solvents for reactions, such as DMF, DCM, and acetonitrile were either used as obtained 
from Sigma-Aldrich or distilled from an appropriate drying agent. All chemicals and reagents used 
were of the highest purity available. Acetonitrile, trifluoroacetic acid, m-cresol and reagents for 
automated PNA synthesis were purchased from Aldrich. The 11-mer Fmoc-protected TAT on resin for 
solid-phase synthesis (Fmoc-YGRRQRKKRRR-PAL-PEG-PS) was purchased from GL Biochem. 
Fmoc-PAL-PEG-PS resin for automated PNA synthesis was purchased from Applied Biosystems. 
PNA(50/5/7)-TAT conjugates were assembled on ExpediteTM 8900 Nucleic Acid Synthesis System 
purchased by Applied Biosystems. And all PNA conjugates were purified by reversed-phase 
high-performance liquid chromatography (HPLC) on a Beckman System Gold instrument equipped 
with a UV-vis array detector, using a Microsorb-MV300-5 C-18 column (250 × 4.6mm column, 300 
Ǻ pore size, Varian Inc.). HPLC fractions were collected and concentrated under vacuum in a 
SpeedVac evaporator (Savant). UV-vis absorption of all PNA conjugates was determined with a 
Bausch and Lomb Spectronic1001 spectrophotometer or a Varian Cary 100 bio UV-vis 
spectrophotometer. The concentration of PNA conjugates was determined by the Beer-Lambert law 
using standard extinction coefficients for the PNA bases at 260nm. All PNA conjugates were 
characterized by MALDI-TOF on a PerSpective Voyager RP MALDI-TOF mass spectrometer in linear 
mode using insulin as the internal reference. A-cyano-4-hydroxycinnamic acid (CHCA) was used as 
the matrix. Fluorescence spectra were measured on a Varian Cary Eclipse fluorescence 
spectrophotometer to determine CMC (critical micelle concentration). DLS data were obtained in dd 
water on Zetasizer Nano ZS using disposable Low Volume Cells purchased from Malvern Instruments 
Inc. Griess and Cell Viability assay kits were both purchased from Promega Inc. 
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Synthesis of PNA(480/240)-TAT conjugates 
Resin Fmoc Deblocking
WASH
WASH
WASH
Fmoc Deblocking
20% Piperidine / DMF
PNA(480/240)-TAT on resin
Activating and Coupling / Capping
0.2M HATU, 0.2M Monomer, Base;
5% Ac2O, 6% 2,6-lutidine, DMF
 
Figure 4.3 Solid-phase synthetic procedure [29] for the synthesis of PNA(480/240)-TAT conjugates 
    PNA(480/240)-TAT conjugates were all prepared by automated standard Fmoc chemistry 
procedures on a 2 μmol scale, in Fmoc-deprotected mode. The resin with PNA(480/240)-TAT 
conjugates was washed with anhydrous DMF (3 × 1 mL) and DCM (3 × 1 mL) respectively, dried 
with nitrogen for cleavage and purification. 
Synthesis of the Lipid-PNA(480/240)-TAT conjugates 
OH
O
TAT-PNA(480/240)
 m-Cresol/TFAn
+
O
N
H
PNA(480/240)-TAT
n
n=10,12,14,16
Lipid-PNA(480/240)-TAT
 DCC/DMAP, DMF
 HPLC
 
Figure 4.4 Solid-phase Synthesis of Lipid-PNA(480/240)-TAT conjugates 
    After the PNA(480/240)-TAT conjugates[30] were prepared on the resin, the resin was washed and 
dried by automated steps and then added into an anhydrous DMF solution (100 μL) containing the 
fatty acid (20 μmol), DCC (20 μmol) and DMAP (20 μmol) and shaken overnight at room 
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temperature. The resin with Lipid-PNA(480/240)-TAT conjugates was washed with anhydrous DMF 
(3 × 1 mL) and DCM (3 × 1 mL) respectively, dried with nitrogen for cleavage and purification. 
Cleavage, Purification and Characterization of PNA(480/240) conjugates 
 m-Cresol / TFA PNA( 480/240) ConjugatesPNA( 480/240 ) Conjugates  HPLC  
Figure 4.5 Cleavage and purification of PNA(480/240) conjugates 
    After the automated synthesis and post-synthetic modification in vials, the resin was incubated in 
400 μL TFA/m-cresol (4:1) [29] for 3 h. The released PNA(480/240)-TAT conjugate was then 
precipitated by the addition of 10 volumes of ice-cold diethyl ether. The crude product was collected by 
centrifugation and purified by reverse phase HPLC with a 65 -min 1 mL/min linear gradient of 5 to 70% 
buffer B (0.1% TFA in CH3CN) in buffer A (0.1%TFA in dd water). The fractions containing the 
desired PNA(480/240) conjugates were evaporated, dissolved in dd water, and characterized by 
MALDI-TOF with a matrix prepared from 1% CHCA in 1:1 ratio of acetonitrile vs 0.1% TFA in dd 
water. 
Determination of Critical Micelle Concentration (CMC) [31] 
Stock solutions of Lipid-PNA(480/240)-TAT conjugates were diluted in water to different 
concentrations. Two buffers, with or without NaCl in 2% methanol/water as (10 μM pyrene, 150 mM 
NaCl, 5 mM Tris, pH=7) and (10 μM pyrene, 5mM Tris, pH=7). Two series of CMC samples were 
made with or without NaCl for each PNA conjugate, by mixing 25 μL buffer and 25 μL of stock 
solutions of different concentrations. Fluorescence emission spectra were obtained by exciting the 
pyrene at 300 nm. The ratio of intensity of the first (373 nm) and third (383nm) emission peaks was 
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plotted against PNA concentration to determine the CMC from the breakpoint in a bilinear fit to the 
data. 
Dynamic Light Scattering (DLS) Analysis [32] 
    Stock solutions of Lipid-PNA(480/240)-TAT conjugates were diluted in water to different 
concentrations. Dynamic light scattering data was used to calculate the average micelle size at different 
concentrations on a Malvern Nano ZS. The average micelle size was plotted against PNA concentration 
to determine the minimum average micelle size range. 
Determination of Partition Ratios [33] 
    Equal volumes of octanol and water were mixed completely and allowed to separate into two clear 
layers. Lipid-PNA(480/240)-TAT conjugates were dissolved in equal volume of the two clear layers. 
The solution was vortexed to allow complete mixing before measuring the concentration of the solute 
in each solvent by UV-vis spectroscopy at 260nm. The partition ratio was calculated as the ratio of the 
absorption in water vs the absorption in 1-octanol. 
Griess Assay of iNOS inhibition by Lipid-PNA480-TAT, PNA480-TAT and PNA480-Lys4 
conjugates (Carried out in our laboratory by Yuefei Shen, and PNA480-Lys4 was Yuefei’s sample)  
    Mouse peritoneal macrophage RAW264.7 (ATCC TIB-71) cells were maintained in DMEM 
containing 10% FBS, streptomycin (100 mg/mL), and penicillin (100 units/mL) at 37 °C in a 
humidified incubator with 5% CO2. RAW264.7 cells were seeded in 24-well plates with 1 × 105 per 
well in 600 mL DMEM with 10% FBS and incubated for 24 h. The cells were then washed three times 
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with PBS, after which 400 mL DMEM (no FBS) and 100 mL opti-MEM (Invitrogen) were added with 
various concentrations of Lipid-PNA480-TAT with CQ (Chloroquine) and Lipid-PNA480-TAT 
without CQ; PNA480-TAT with CQ or without CQ, PNA480-Lys4 with CQ or without CQ; with or 
without different controls like siRNA481, Lipo (Lipofectamine 2000), CQ (Chloroquine), Lipo & CQ, 
and LPS (Lipopolysaccharides). 6 h later, LPS (Lipopolysaccharides from Escherichia coli 055:B5, 
Sigma, 1 mg/mL), IFN-g (mouse, recombinant, E. coli, Calbiochem, 100 ng/mL; LPS), and 60 mL FBS 
were added with DMEM to make a total of 600 mL and further incubated. After an additional 18 h, an 
aliquot of the supernatant (50 mL) was removed for assay of NO by the Griess assay (Promega) and 
quantified by the absorbance at 540 nm. 
Cytotoxicity Assay of Lipid-PNA480-TAT, PNA480-TAT and PNA480-Lys4 conjugates 
The cytotoxicity of the PNAs was evaluated by the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega Co.). Mouse peritoneal macrophage RAW264.7 (ATCC TIB-71) cells were seeded in 
a 96-well plate at a density of 1×104 cells/well and cultured for 24 h in 100 μL DMEM containing 10% 
FBS. Thereafter, the medium was replaced with 100 μL fresh medium containing various 
concentrations of Lipid-PNA480-TAT with CQ (Chloroquine) and Lipid-PNA480-TAT without CQ; 
PNA480-TAT with CQ or without CQ, PNA480-Lys4 with CQ or without CQ; with or without 
different controls like siRNA481, Lipo (Lipofectamine 2000), CQ (Chloroquine), Lipo & CQ, and LPS 
(Lipopolysaccharides). After 24 h incubation at 37 °C, 100 μL of CellTiter-Glo reagent were added. 
The contents were mixed, and the plate was allowed to incubate at room temperature for 10 minutes to 
stabilize the luminescence signal. Luminescence intensities were recorded on a Luminoskan Ascent 
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luminometer (Thermo Scientific) with an integration time of 1s per well. The relative cell viability was 
calculated as the ratio of the luminescence in the presence and absence of PNA conjugates. 
 
4.4 Result and Discussion 
Eight antisense Lipid-PNA(480/240)-TAT conjugates and three controls were synthesized and 
characterized by MALDI, and their CMC, DLS sizes, and partition ratios. As shown below, MALDI 
(matrix-assisted laser desorption ionization) was used to identify the HPLC fraction containing the 
PNA conjugates (Table 4.2). 
Table 4.1 Sequences of PNA-TAT used in PNA480-TAT, PNA480(MM)-TAT, PNA240-TAT 
Sample Sequence 
PNA480-TAT TGAAATCCGATGTGGCCT-YGRKKRRQRRR 
PNA480(MM)-TAT TAGAATCCAGTGGTGCCT-YGRKKRRQRRR 
PNA240-TAT TGTCCTTTTCCTCTTTCA-YGRKKRRQRRR 
 
Table 4.2 MALDI for Lipid-PNA(480/240)-TAT and PNA(480/240)-TAT conjugates 
Sample Cal MW MALDI 
Figure No 
(Appendix) 
Ste-PNA480-TAT 6717 6727.55 Figure A4.15
Pal-PNA480-TAT 6689 6703.55 Figure A4.12
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Ted-PNA480-TAT 6661 6674.86 Figure A4.9 
Lau-PNA480-TAT 6633 6642.08 Figure A4.6 
PNA480-TAT 6451 6446.6 Figure A4.3 
PNA480(MM)-TAT 6451 6449.1 Figure A4.18
Ste-PNA240-TAT 6560 6567.63 Figure A4.33
Pal-PNA240-TAT 6532 6537.73 Figure A4.30
Ted-PNA240-TAT 6504 6515.89 Figure A4.27
Lau-PNA240-TAT 6476 6486 Figure A4.24
PNA240-TAT 6294 6292.8 Figure A4.21
    The critical micelle concentrations (CMC) of eleven Lipid-PNA-TAT conjugates were determined 
by using a pyrene-based fluorescence assay in two aqueous buffers of with NaCl or without NaCl. And 
it was demonstrated that CMC values of almost all Lipid-PNA-TAT conjugates in the aqueous buffer 
with NaCl were lower than the values of the corresponding Lipid-PNA-TAT conjugates in the aqueous 
buffer without NaCl, except Ste-PNA480-TAT (Table 4.3). This trend was also found by Gang Shen [34] 
for lipid-PNA-R9 conjugates, which were used in the Luciferase splice-correction assays. The 
similarity is probably because the positively charged TAT group contains several arginine and lysine 
residues that confer a similar positive charge as does the Arg9 peptide. 
Considering the different lengths of the lipid chains used in those lipid-PNA-TAT conjugates, no 
apparent relation or trend was found between the length of the lipid chains and the CMC values, 
probably because the differences between the lengths of lipid chains were too small to be show any 
 99 
 
detectable differences from CMC tests, or because the sensitivity of CMC tests was not enough by 
pyrene-based fluorescence assays. 
Table 4.3 CMC for Lipid-PNA(480/240)-TAT and PNA(480/240)-TAT conjugates 
Sample 
CMC 
(w/NaCl μM) 
Figure No 
(Appendix) 
CMC 
(w/o NaCl μM) 
Figure No 
(Appendix) 
Ste-PNA480-TAT 12.5 Figure A4.49 9.4 Figure A4.48
Pal-PNA480-TAT 11.3 Figure A4.47 18.8 Figure A4.46
Ted-PNA480-TAT 9.4 Figure A4.45 18.8 Figure A4.44
Lau-PNA480-TAT 14 Figure A4.43 14.1 Figure A4.42
Ste-PNA240-TAT 13 Figure A4.57 15.6 Figure A4.56
Pal-PNA240-TAT 18.8 Figure A4.55 25 Figure A4.54
Ted-PNA240-TAT 9.4 Figure A4.53 15.6 Figure A4.52
Lau-PNA240-TAT 19.5 Figure A4.51 23.4 Figure A4.50
Because these Lipid-PNA-TAT conjugates contained hydrophobic tails and hydrophilic 
PNA-TAT parts, it was likely that those amphiphilic conjugates would form micelles in aqueous phase, 
which might explain their better uptake into cells through endocytosis or membrane fusion. [30] DLS 
suggested that the possible vesicle sizes formed from Lipid-PNA-TAT conjugates in the aqueous phase 
was in the range of 200-400 nm (Table 4.4). This size range falls into the category of large vesicles 
with spherical shape, which may be optimal for macropinocytosis, instead of micelle-induced 
intracellular delivery. The relatively large vesicles size formed from those Lipid-PNA-TAT conjugates 
 100 
 
in the aqueous phase was probably due to the lack of the strong enough electronic repulsion at the ends, 
while PNA and lipid chain was neutral. 
Table 4.4 DLS for Lipid-PNA(480/240)-TAT and PNA(480/240)-TAT conjugates 
Sample DLS (nm) 
Figure No 
(Appendix) 
Ste-PNA480-TAT 283.5 Figure A4.37
Pal-PNA480-TAT 415.5 Figure A4.36
Ted-PNA480-TAT 234 Figure A4.35
Lau-PNA480-TAT 232 Figure A4.34
Ste-PNA240-TAT 213.4 Figure A4.41
Pal-PNA240-TAT 320.3 Figure A4.40
Ted-PNA240-TAT 245.1 Figure A4.39
Lau-PNA240-TAT 341.3 Figure A4.38
The partition ratios showed that most of the Lipid-PNA-TAT conjugates were dissolved in the 
aqueous phase instead of the organic octanol phase, which is consistent with micelle formation that 
only exposed the hydrophilic TAT peptide to the water and sequestered the highly hydrophobic lipid 
portion (Table 4.5). 
Table 4.5 Partition Ratio for Lipid-PNA(480/240)-TAT and PNA(480/240)-TAT conjugates 
Sample 
Partition Ratio  
(dd water/octanol) 
 101 
 
Ste-PNA480-TAT 170.8 
Pal-PNA480-TAT 139.14 
Ted-PNA480-TAT 147.6 
Lau-PNA480-TAT 143.75 
Ste-PNA240-TAT 210.76 
Pal-PNA240-TAT 369.1 
Ted-PNA240-TAT 373.8 
Lau-PNA240-TAT 334.5 
 
The lipidated PNA-TAT conjugates were then tested for their ability to inhibit iNOS induction by 
monitoring the production of nitric oxide.  It was found that iNOS inhibition increased with the 
increasing length of lipid chain, however, the cytotoxicity also increased as well (Figure 4.6 and Figure 
4.7). (Lipid-PNA, 2 μM) 
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Figure 4.6 Griess Assay of iNOS Inhibition by Lipid-PNA480-TAT, PNA480-TAT and PNA480-Lys4 
conjugates 
 
Figure 4.7 Cell Viability Assay of Lipid-PNA480-TAT, PNA480-TAT and PNA480-Lys4 conjugates 
The Griess and cytotoxicity assays were then carried out at different concentrations of 
Lipid-PNA480-TAT, PNA480-TAT and PNA480-Lys4 conjugates to find out the optimal 
concentration for iNOS inhibition. At 0.5 μM PNA almost no iNOS relative inhibition was observed 
but then it increased along with increasing cytotoxicity. When the NO production was divided by cell 
viability to measure the NO relative production, the Ste-PNA480-TAT conjugate and 
Pal-PNA480-TAT conjugate both showed the low NO relative production at 2 μM (Figure 4.8). To be 
more specific, at 2 μM the NO relative Production value of Ste-PNA480-TAT conjugate was the 
lowest as 0.35, and at 2 μM the NO relative Production value of Pal-PNA480-TAT conjugate was the 
lowest as 0.3 (Figure 4.9). Considering the concentration used at 1 μM, Ste-PNA480-TAT conjugate 
showed the best relative iNOS inhibition among all the PNA conjugates, while at the concentration of 2 
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μM Pal-PNA480-TAT conjugate showed the best relative iNOS inhibition among all the PNA 
conjugates (Figure 4.9). 
 
Figure 4.8 Griess Assay of NO relative Production divided by Cell Viability by Lipid-PNA480-TAT, 
PNA480-TAT and PNA480-Lys4 conjugates 
 
Figure 4.9 Griess Assay of NO relative production divided by cell viability by Lipid-PNA480-TAT, 
PNA480-TAT and PNA480-Lys4 conjugates 
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    Since 90% of cells died with 100 μM CQ to facilitate the intracellular delivery of 
Lipid-PNA480-TAT conjugate and the Lipofectamine 2000 was proven to be of much less cytotoxicity 
and little iNOS inhibition. Different concentrations of Lipofectamine 2000 were tested for their ability 
to improve iNOS inhibition of the PNA conjugates at 1 μM concentration. Although 
Ste-PNA480-TAT showed better iNOS inhibition at 20 μM of Lipofectamine 2000 than that at 10 μM 
as far as NO production was concerned, the very low cell viability value made the relative NO 
production divided by cell viability at 20 μM Lipofectamine 2000 not as good as that at 10 μM 
Lipofectamine 2000. And according to these results from Griess assay and the cell viability assay, the 
best iNOS inhibition was observed at10 μM Lipofectamine 2000 when 1 μM of Ste-PNA480-TAT 
and Pal-PNA480-TAT conjugates were used (Figure 4.10). 
 
 
Figure 4.10 Griess Assay of NO relative Production divided by Cell Viability of Lipid-PNA480-TAT, 
PNA480-TAT and PNA480-Lys4 conjugates with different concentrations of Lipofectamine 
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    To obtain better iNOS inhibition, a deeper understanding of the complex mechanisms concerning 
inflammation in lung injury will be required along with improved antisense agents. One possible 
improvement may be to attach a phospholipid [34] or a perfluoroacid chain [35] to the PNA conjugates 
which may form micelles of smaller size that may be better taken up through endocytosis. 
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Chapter 5 Conclusions and Future Directions 
    In this thesis, three series of Lipid-PNA-CPP (TAT/R9) conjugates were designed, synthesized 
and characterized by MALDI, UV-vis, partition coefficients CMC and DLS. Selected PNAs were also 
evaluated for their ability to inhibit telomerase, iNOS production, and to image breast cancer. The goal 
was to see if an improved intracellular delivery of the neutral PNA conjugates could be obtained, via 
self-assembly of the amphiphilic PNA conjugates in aqueous environment to form vesicles. All the 
lipidated PNA-CPP conjugates showed and ability to form micelles in solution at about 10 µM 
concentration, and to greatly favor water over octanol.  The vesicles formed, however, appeared to be 
much larger than expected, and could be considered rather large at 200-300 nM, which may explain 
their bioactivity and biodistribution properties. 
In a very limited study of lipidated PNAs targeting human telomerase, only P(CN)-Telm-R9 and 
Ted-Telm-R9 conjugates showed detectable telomerase inhibition.  This was unexpected given 
previous studies which showed that lipidation, and in particular phospholipidated, improved the ability 
of PNA-Arg9 to correct a splicing error in HeLa cells.  Clearly the studies would have to be repeated 
before any solid conclusions can be drawn about their effectiveness as telomerase inhibitors. 
    More detailed studies of iNOS inhibition by the lipidated PNA-CPP conjugates showed that the 
Ste-PNA480-TAT conjugate with the longest lipid chain showed the best iNOS inhibition at 1 μM, 
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and Pal-PNA480-TAT conjugate with the second longest lipid chain showed the best inhibition at 2 μ
M. The extent of iNOS inhibition could be improved by addition of Lipofectamine 2000, which could 
be explained by assembly of the lipidated PNAs with the cationic liposomes formed by 
Lipofectamine. 
The lipidated Pal-PNA50-(76Br)TAT showed greatly improved biodistribution in mice compared to the 
64Cu64-DOTA-Y-PNA50-K4, being retained in the blood to a much greater extent with a %ID/gram 
of 1.8 at 24 hours, and not being excreted very quickly.  There was however significant liver uptake 
which might have been due to the large vesicle size of 200-300 nm.  Also, no tumor specificity was 
observed, suggesting that either the tumor was oversaturated with the PNA imaging agent or that the 
PNA was not entering the tumor cells.  It may be that lipidated PNAs that form smaller vesicles or 
micelles will show even greater blood retention and better tumor specificity. 
While the current set of lipidated PNA-CPP conjugates is promising, far more work will be needed to 
further develop these conjugates as practical agents for imaging and therapy.  Potential avenues for 
further development are fluorinated lipids, and methods of attachment of the lipid to the PNA that can 
be cleaved by endogenous enzymes or the lower pH found in endosomes to facilitate release of the 
PNA.  Also fluorescent probes could be attached to facilitate tracking of the conjugates inside cells 
to ascertain their mechanism of entry by confocal microscopy. 
  
 
 
 110 
 
  
 111 
 
Appendix_Chapter 2 
HPLC, UV, MALDI 
 
Figure A2.1 HPLC of Crude TelmR9 (major peak, collecting 18min-19.5min) 
 
 
Figure A2.2 UV of TelmR9 
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Figure A2.3 MALDI of TelmR9 
 
Figure A2.4 HPLC of Crude Pal-TelmR9 (second major peak, collecting 28min-30min) 
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Figure A2.5 UV of Pal-TelmR9 
 
 
Figure A2.6 MALDI of Pal-TelmR9 
 
 
Figure A2.7 HPLC of Crude Ted-TelmR9 
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Figure A2.8 UV of Ted-TelmR9 
 
 
Figure A2.9 MALDI of Ted-TelmR9 
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Figure A2.10 HPLC of Crude Ste-TelmR9 
 
 
Figure A2.11 UV of Ste-TelmR9 
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Figure A2.12 MALDI of Ste-TelmR9 
 
 
 
Figure A2.13 HPLC of Crude Pal-P-TelmR9 
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Figure A2.14 UV of Pal-P-TelmR9 
 
 
Figure A2.15 MALDI of Pal-P-TelmR9 
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Figure A2.16 HPLC of Crude P-TelmR9 
 
 
Figure A2.17 UV of P-TelmR9 
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Figure A2.18 MALDI of P-TelmR9 
 
 
Figure A2.19 HPLC of Crude P(CN)-TelmR9 
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Figure A2.20 UV of P(CN)-TelmR9 
 
 
Figure A2.21 MALDI of P(CN)-TelmR9 
 
 
DLS, CMC 
C(μM) I373/I383 
0.007 1.489592 
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Figure A2.22 Ted-Telm-R9_CMC_without NaCl 
 
 
 
1.42
1.43
1.44
1.45
1.46
1.47
1.48
1.49
1.5
0.001 0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 0.014 1.481585 
0.028 1.494602 
0.0561 1.486009 
0.2245 1.484102 
0.898 1.493159 
3.593 1.490662 
7.187 1.490957 
14.375 1.487184 
28.75 1.469855 
57.5 1.459077 
115 1.445387 
230 1.425188 C(μM) I373/I383 
0.014 1.564565 
0.028 1.565888 
0.0561 1.564237 
0.1122 1.557741 
0.449 1.558463 
1.796 1.562648 
3.593 1.557264 
7.187 1.567101 
14.375 1.544717 
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Figure A2.23 Ted-Telm-R9_CMC_with NaCl 
 
 
 
 
 
 
1.42
1.44
1.46
1.48
1.5
1.52
1.54
1.56
1.58
0.001 0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 57.5 1.508859 
115 1.478573 
230 1.438731 
C(μM) I373/I383 
0.007 1.49728 
0.014 1.497403 
0.028 1.49194 
0.0561 1.491416 
0.1122 1.503641 
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Figure A2.24 Pal-Telm-R9_CMC_without NaCl 
 
 
 
1.42
1.43
1.44
1.45
1.46
1.47
1.48
1.49
1.5
1.51
0.001 0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 0.2245 1.492667 
0.449 1.497314 
0.898 1.488354 
1.796 1.501953 
3.593 1.496456 
7.187 1.494717 
14.375 1.49172 
28.75 1.471479 
57.5 1.455226 
115 1.439605 
230 1.427022 
C(μM) I373/I383 
0.007 1.538614 
0.028 1.535606 
0.0561 1.547129 
0.1122 1.506758 
0.2245 1.534514 
0.449 1.490662 
1.796 1.485111 
3.593 1.534557 
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Figure A2.25 Pal-Telm-R9_CMC_with NaCl 
 
 
 
 
 
1.25
1.3
1.35
1.4
1.45
1.5
1.55
1.6
0.001 0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 7.187 1.521369 
14.375 1.511606 
28.75 1.447094 
57.5 1.405209 
115 1.34771 
230 1.298826 
C(μM) I373/I383 
0.0046 1.474278 
0.00915 1.462107 
0.0366 1.464239 
0.07325 1.467733 
0.1465 1.46105 
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Figure A2.26 Ste-Telm-R9_CMC_without NaCl 
 
 
1.34
1.36
1.38
1.4
1.42
1.44
1.46
1.48
1.5
0.001 0.01 0.1 1 10 100
I373/I383‐Log[Conc] (1/Log[μM]) 0.586 1.467712 
1.172 1.461071 
2.344 1.471603 
4.6875 1.471599 
9.375 1.43791 
18.75 1.411696 
37.5 1.380256 
75 1.36202 
C(μM) I373/I383 
0.0046 1.502483 
0.00915 1.504624 
0.0183 1.503585 
0.07325 1.502258 
0.1465 1.508147 
0.293 1.501909 
0.586 1.50954 
1.172 1.508971 
2.344 1.505241 
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Figure A2.27 Ste-Telm-R9_CMC_with NaCl 
 
 
 
 
 
1.36
1.38
1.4
1.42
1.44
1.46
1.48
1.5
1.52
0.001 0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 4.6875 1.501257 
9.375 1.487843 
18.75 1.459117 
37.5 1.425819 
75 1.40639 
150 1.374231 
C(μM) I373/I383 
0.007 1.466884 
0.014 1.470579 
0.029 1.46447 
0.115 1.467743 
0.23 1.467847 
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Figure A2.28 Pal-P-Telm-R9_CMC_without NaCl 
 
 
 
1.28
1.3
1.32
1.34
1.36
1.38
1.4
1.42
1.44
1.46
1.48
1.5
0.001 0.01 0.1 1 10 100
I373/I383‐Log[Conc] (1/Log[μM]) 0.46 1.460247 
0.94 1.475048 
1.875 1.466211 
3.75 1.47215 
7.5 1.458236 
15 1.405613 
30 1.342321 
60 1.301647 
C(μM) I373/I383 
0.007 1.467015 
0.014 1.466367 
0.029 1.469527 
0.0575 1.462331 
0.115 1.467442 
0.46 1.461654 
0.94 1.462199 
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Figure A2.29 Pal-P-Telm-R9_CMC_with NaCl 
 
 
 
 
HPLC, UV, MALDI 
 
Figure A2.30 HPLC of Crude Telm-TAT 
1.32
1.34
1.36
1.38
1.4
1.42
1.44
1.46
1.48
0.001 0.01 0.1 1 10 100
I373/I383‐Log[Conc] (1/Log[μM]) 1.875 1.459948 
3.75 1.465002 
7.5 1.431186 
15 1.405136 
30 1.36912 
60 1.338266 
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Figure A2.31 UV of Telm-TAT 
 
 
Figure A2.32 MALDI of Telm-TAT 
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Figure A2.33 HPLC of Crude Ted-Telm-TAT 
 
 
Figure A2.34 UV of Ted-Telm-TAT 
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Figure A2.35 MALDI of Ted-Telm-TAT 
 
Figure A2.36 HPLC of Crude Pal-Telm-TAT 
 
 
 132 
 
Figure A2.37 UV of Pal-Telm-TAT 
 
 
Figure A2.38 MALDI of Pal-Telm-TAT 
 
Figure A2.39 HPLC of Crude Ste-Telm-TAT 
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Figure A2.40 UV of Ste-Telm-TAT 
 
 
Figure A2.41 MALDI of Ste-Telm-TAT 
 
Appendix_Chapter 3 
HPLC, UV, MALDI 
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Figure A3.1 HPLC of Crude PNA50-TAT (major peak, collecting 16.3min-17.5min) 
 
 
Figure A3.2 UV of PNA50-TAT 
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Figure A3.3 MALDI of PNA50-TAT 
 
Figure A3.4 HPLC of Crude PNA50S-TAT 
 
 
Figure A3.5 UV of PNA50S-TAT 
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Figure A3.6 MALDI of PNA50S-TAT 
 
Figure A3.7 HPLC of Crude Pal-PNA50-TAT 
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Figure A3.8 UV of Pal-PNA50-TAT 
 
Figure A3.9 MALDI of Pal-PNA50-TAT 
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Figure A3.10 HPLC of Crude Lau-PNA50-TAT 
 
 
Figure A3.11 UV of Lau-PNA50-TAT 
 139 
 
 
Figure A3.12 MALDI of Lau-PNA50-TAT 
 
Figure A3.13 HPLC of Crude Ted-PNA50-TAT 
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Figure A3.14 UV of Ted-PNA50-TAT 
 
Figure A3.15 MALDI of Ted-PNA50-TAT 
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Figure A3.16 HPLC of Crude Ste-PNA50-TAT 
 
 
Figure A3.17 UV of Ste-PNA50-TAT 
 
 
Figure A3.18 MALDI of Ste-PNA50-TAT 
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Figure A3.19 HPLC of Crude PNA5-TAT 
 
 
Figure A3.20 UV of PNA5-TAT 
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Figure A3.21 MALDI of PNA5-TAT 
 
Figure A3.22 HPLC of Crude Lau-PNA5-TAT 
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Figure A3.23 UV of Lau-PNA5-TAT 
 
Figure A3.24 MALDI of Lau-PNA5-TAT 
 
 
Figure A3.25 HPLC of Crude Ted-PNA5-TAT 
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Figure A3.26 UV of Ted-PNA5-TAT 
 
Figure A3.27 MALDI of Ted-PNA5-TAT 
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Figure A3.28 HPLC of Crude Pal-PNA5-TAT 
 
 
Figure A3.29 UV of Pal-PNA5-TAT 
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Figure A3.30 MALDI of Pal-PNA5-TAT 
 
Figure A3.31 HPLC of Crude Ste-PNA5-TAT 
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Figure A3.32 UV of Ste-PNA5-TAT 
 
Figure A3.33 MALDI of Ste-PNA5-TAT 
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Figure A3.34 HPLC of Crude PNA7-TAT 
 
 
Figure A3.35 UV of PNA7-TAT 
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Figure A3.36 MALDI of PNA7-TAT 
 
Figure A3.37 HPLC of Crude Ted-PNA7-TAT 
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Figure A3.38 UV of Ted-PNA7-TAT 
 
Figure A3.39 MALDI of Ted-PNA7-TAT 
 
Figure A3.40 HPLC of Crude Pal-PNA7-TAT 
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Figure A3.41 UV of Pal-PNA7-TAT 
 
Figure A3.42 MALDI of Pal-PNA7-TAT 
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Figure A3.43 HPLC of Crude Ste-PNA7-TAT 
 
 
Figure A3.44 UV of Ste-PNA7-TAT 
 
Figure A3.45 MALDI of Ste-PNA7-TAT 
 
DLS, CMC 
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Figure A3.46 Lau-PNA50-TAT_DLS 
 
 
 
 
  
100
200
300
400
500
600
700
800
900
1000
1100
0.001 0.1 10 1000
Z‐Avg/Log[Conc]  (d.nm/Log[μM]) Conc (μM)  Z‐Ave (d.nm)  PdI 
2417.382  758  0.685 
1136.16954  850.5  0.628 
568.08477  685.7  0.587 
284.042385  778  0.614 
142.021193  545.8  0.619 
71.0105963  653  0.667 
35.5052981  635.2  0.682 
8.87632453  545.2  0.776 
4.43816227  395.1  0.588 
2.21908113  247.4  0.481 
1.10954057  268.1  0.539 
0.55477028  332.6  0.486 
0.27738514  403.8  0.635 
0.06934629  641  0.89 
0.03467314  953.7  1 
0.01733657  912.3  0.811 
0.00866829  1003  0.947 
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Figure A3.47 Ted-PNA50-TAT_DLS 
 
 
 
 
 
 
 
 
 
 
250
350
450
550
650
750
850
0.0001 0.01 1 100 10000
Z‐Ave/Log[Conc] (d.nm/Log[μM]) Conc (μM)  Z‐Ave (d.nm)  PdI 
1445.538  475.2  0.724 
679.40286  511.4  0.71 
339.70143  489.6  0.578 
169.850715  529  0.559 
84.9253575  538.4  0.655 
42.46267875  560.2  0.707 
21.23133938  447.3  0.501 
10.61566969  337.9  0.538 
5.307834844  407.2  0.689 
2.653917422  359.7  0.537 
1.326958711  432.1  0.72 
0.663479355  303.9  0.586 
0.331739678  313.6  0.614 
0.165869839  377.6  0.781 
0.04146746  526.8  0.531 
0.02073373  406.6  0.418 
0.005183432  502.3  0.619 
0.002591716  610  0.707 
0.001295858  780.5  0.7 
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Figure A3.48 Pal-PNA50-TAT_DLS 
 
 
 
 
 
  
0
100
200
300
400
500
600
700
800
0.001 0.1 10 1000
Z‐Avg/Log[Conc] (d.nm/Log[μM]) Conc (μM)  Z‐Ave (d.nm)  PdI 
2269.25  42.26  1 
1066.5475  39.93  1 
533.27375  48.99  1 
133.318438  128.8  0.473 
66.6592188  157.5  0.423 
33.3296094  172.9  0.39 
16.6648047  215  0.393 
8.33240234  197.4  0.371 
4.16620117  227.2  0.437 
2.08310059  221.5  0.369 
1.04155029  222.2  0.349 
0.52077515  454.1  0.491 
0.26038757  362.5  0.365 
0.06509689  560.8  0.507 
0.03254845  493.3  0.452 
0.01627422  732  0.873 
0.00813711  607.4  0.549 
0.00406856  691.9  0.542 
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Figure A3.49 Ste-PNA50-TAT_DLS 
 
 
 
 
  
200
300
400
500
600
700
800
900
1000
0.001 0.01 0.1 1 10 100 1000
Z‐Ave/Log[Conc] (d.nm/Log[μM])
Conc (μM)  Z‐Ave (d.nm)  PdI 
924.557  341.8  0.529 
434.54179  343.2  0.46 
217.270895  319.2  0.489 
108.635448  362.3  0.405 
54.3177238  364.7  0.49 
27.1588619  379.3  0.477 
13.5794309  319.2  0.557 
6.78971547  320.5  0.523 
3.39485773  371.6  0.501 
1.69742887  316.2  0.602 
0.84871443  359.7  0.594 
0.21217861  290.2  0.46 
0.1060893  356.2  0.512 
0.05304465  417.8  0.612 
0.02652233  548.5  0.684 
0.01326116  863.4  0.785 
0.00331529  759.8  0.827 
0.00165765  912.6  0.739 
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Conc (μM)  Z‐Ave (d.nm)  PdI 
1517.346  94.53  0.531 
713.15262  89.29  0.58 
379.3365  94.16  0.389 
178.288155  91.4  0.434 
94.834125  82.8  0.31 
44.57203875  89.22  0.368 
23.70853125  82.13  0.313 
11.14300969  86.97  0.323 
5.927132813  87.51  0.297 
2.785752422  92.49  0.264 
1.481783203  100.1  0.279 
0.696438105  103.3  0.316 
0.370445801  103.2  0.29 
0.174109526  105.9  0.308 
0.09261145  119  0.397 
0.043527382  108.4  0.303 
0.023152863  152.8  0.395 
0.010881845  162.7  0.377 
0.005788216  143  0.461 
0.002720461  170.9  0.42 
 160 
 
 
Figure A3.50 Lau-PNA5-TAT_DLS 
 
 
 
 
 
 
 
 
 
 
 
0
100
200
300
400
500
600
700
0.000001 0.0001 0.01 1 100 10000
Z‐Avg/ Log[Conc]  (d.nm/Log[μM]) 0.001447054  198.6  0.426 
0.000680115  212.7  0.465 
0.000361763  326.3  0.545 
0.000170029  269.4  0.51 
9.04409E‐05  435.9  0.74 
4.25072E‐05  415.9  0.693 
5.3134E‐06  623.4  0.802 
2.6567E‐06  577.8  0.601 
1.32835E‐06  572.3  0.687 
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Conc (μM)  Z‐Ave (r. nm)  PdI 
1514.769  91.21  0.579 
711.94143  91.63  0.66 
355.970715  96.73  0.772 
177.9853575  90.13  0.428 
88.99267875  81.02  0.458 
44.49633938  77.23  0.372 
22.24816969  79.31  0.275 
11.12408484  84.26  0.239 
5.562042422  94.8  0.354 
2.781021211  96.58  0.383 
1.390510605  93.28  0.287 
0.695255303  106.1  0.325 
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Figure A3.51 Ted-PNA5-TAT_DLS 
 
 
 
 
 
 
 
 
 
 
50
100
150
200
250
300
0.000010.00010.001 0.01 0.1 1 10 100 1000
Z‐Ave/Log[Conc] (d.nm/Log[μM]) 0.347627651  101.9  0.293 
0.173813826  104.2  0.284 
0.086906913  117.2  0.395 
0.043453456  104.2  0.298 
0.021726728  107.3  0.354 
0.010863364  94.7  0.339 
0.005431682  97.02  0.406 
0.002715841  115.5  0.345 
0.001357921  131.7  0.428 
0.00067896  179.7  0.541 
0.00033948  222.9  0.535 
0.00016974  170.2  0.467 
8.487E‐05  191.3  0.669 
4.2435E‐05  247.8  0.553 
2.12175E‐05  211.8  0.616 
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Conc (μM)  Z‐Ave (r.nm)  PdI 
1244.3  368.4  0.577 
584.821  323.1  0.54 
292.4105  336  0.542 
146.20525  199.6  0.51 
73.102625  155  0.55 
36.5513125  158.8  0.51 
18.2756563  179  0.617 
9.13782813  184.2  0.53 
4.56891406  185.3  0.632 
2.28445703  182.7  0.572 
1.14222852  185.6  0.55 
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Figure A3.52 Pal-PNA5-TAT_DLS 
 
 
 
 
 
 
 
 
 
 
 
100
200
300
400
500
600
700
800
0.001 0.1 10 1000
Z‐Avg/Log[Conc] (d.nm/Log[μM]) 0.57111426  263.1  0.481 
0.28555713  341.4  0.586 
0.07138928  481.1  0.653 
0.03569464  532.9  0.64 
0.01784732  497.5  0.692 
0.00892366  487.6  0.73 
0.00223092  600  0.846 
0.00111546  706.9  0.855 
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Conc (μM)  Z‐Ave (d.nm)  PdI 
1349.9  142.3  0.775 
634.453  126.3  0.882 
317.2265  186.2  0.597 
158.61325  174.9  0.589 
79.306625  195.5  0.463 
39.6533125  176.7  0.39 
19.82665625  194.8  0.337 
9.913328125  171.5  0.317 
4.956664063  179.6  0.302 
2.478332031  188.2  0.359 
1.239166016  191.7  0.355 
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Figure A3.53 Ste-PNA5-TAT_DLS 
 
 
 
 
 
 
 
 
 
 
 
0
100
200
300
400
500
600
700
0.0001 0.01 1 100 10000
Z‐Avg/Log[Conc] (d.nm/Log[μM]) 0.619583008  204.9  0.36 
0.309791504  213  0.331 
0.154895752  210.8  0.318 
0.077447876  236.2  0.392 
0.038723938  239  0.405 
0.019361969  235.4  0.399 
0.009680984  297.5  0.43 
0.004840492  357.8  0.433 
0.002420246  337.7  0.457 
0.001210123  481.8  0.514 
0.000302531  594.4  0.65 
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Conc (μM)  Z‐Ave (d.nm)  PdI 
962.52  211.5  0.533 
452.3844  142.7  0.932 
113.0961  175.5  0.627 
56.54805  224.1  0.689 
28.274025  241.2  0.467 
14.1370125  238.7  0.415 
7.06850625  240.1  0.478 
3.53425313  252.2  0.387 
1.76712656  280.5  0.392 
0.88356328  260.1  0.396 
0.44178164  277.9  0.359 
0.22089082  330.6  0.453 
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 Figure A3.54 Ted-PNA7-TAT_DLS 
 
 
 
  
100
200
300
400
500
600
700
800
0.00010.001 0.01 0.1 1 10 100 1000
Z‐Ave/Log[Conc] (d.nm/Log[μM]) 0.11044541  318.9  0.473 
0.05522271  345.4  0.475 
0.02761135  380.5  0.397 
0.01380568  445.2  0.511 
0.00690284  480.6  0.654 
0.00172571  526.4  0.527 
0.00043143  556.3  0.543 
0.00021571  689  0.611 
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Figure A3.55 Pal-PNA7-TAT_DLS 
 
 
 
 
  
0
100
200
300
400
500
600
700
800
900
1000
0.001 0.1 10 1000
Z‐Avg/Log[Conc] (d.nm/Log[μM]) Conc (μM)  Z‐Ave (d.nm)  PdI 
1443.9  250.7  0.436 
678.633  91.11  0.774 
339.3165  132.6  0.77 
169.65825  111.3  0.925 
84.829125  193  0.689 
42.4145625  234.6  0.381 
21.2072813  238.9  0.502 
10.6036406  214.3  0.433 
5.30182031  204  0.151 
2.65091016  272.6  0.399 
1.32545508  339.4  0.492 
0.66272754  397.5  0.446 
0.33136377  520.5  0.556 
0.16568188  551.2  0.535 
0.08284094  573.4  0.489 
0.04142047  711.8  0.555 
0.02071024  617.8  0.567 
0.00517756  875.7  0.685 
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Figure A3.56 Ste-PNA7-TAT_DLS  
 
 
 
 
 
0
100
200
300
400
500
600
700
800
0.001 0.1 10 1000
Z‐Avg/Log[Conc] (d.nm/Log[μM]) Conc (μM)  Z‐Ave (d.nm)  PdI 
952.8  82.16  0.926 
447.816  92.95  0.834 
223.908  156.8  0.426 
111.954  108.5  0.927 
55.977  183.9  0.488 
27.9885  184.9  0.449 
13.99425  222.7  0.395 
6.997125  213.6  0.342 
3.4985625  259.5  0.401 
1.74928125  272.3  0.543 
0.87464063  306.2  0.433 
0.43732031  385.3  0.664 
0.21866016  481.8  0.504 
0.10933008  527.6  0.514 
0.05466504  537.8  0.545 
0.02733252  521.1  0.503 
0.00683313  684.7  0.585 
0.00341656  660.4  0.639 
Conc(μM)  I373/I383 
0.073242  1.404998 
0.073242  1.403494 
0.146484  1.39044 
0.292969  1.386537 
 171 
 
 
Figure A3.57 Lau-PNA50-TAT_CMC_without NaCl 
 
 
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc]  (1/Log[μM])   0.585936  1.386483 
1.171875  1.38756 
2.34375  1.356266 
4.6875  1.381842 
9.375  1.356513 
18.75  1.294857 
37.5  1.215593 
150  1.062168 
300  0.931826 
Conc (μM)  I373/I383 
0.073242  1.413549 
0.146484  1.410754 
0.292969  1.416197 
0.585936  1.405095 
1.171875  1.399434 
2.34375  1.41277 
4.6875  1.398416 
9.375  1.404099 
18.75  1.337945 
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Figure A3.58 Lau-PNA50-TAT_CMC_with NaCl 
 
 
 
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc]  (1/Log[μM])   37.5  1.177535 
75  1.051559 
150  0.952677 
300  0.857981 
Conc(μM)  I373/I383 
0.109863  1.340022 
0.219727  1.344872 
0.439453  1.340209 
0.878906  1.35444 
1.757813  1.349269 
3.515625  1.325332 
7.03125  1.356878 
14.0625  1.316379 
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Figure A3.59 Ted-PNA50-TAT_CMC_without NaCl 
 
 
 
 
 
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc]  (1/Log[μM])   28.125  1.238023 
56.25  1.010434 
112.5  0.791126 
225  0.672177 
Conc(μM)  I373/I383 
0.054932  1.396002 
0.109863  1.429219 
0.219727  1.403175 
0.439453  1.412767 
0.878906  1.43128 
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Figure A3.60 Ted-PNA50-TAT_CMC_with NaCl 
 
 
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc]  (1/Log[μM])   1.757813  1.41046 
3.515625  1.429787 
7.03125  1.388973 
14.0625  1.285161 
28.125  1.216224 
56.25  0.983569 
112.5  0.806825 
225  0.689082 
Conc(μM)  I373/I383 
0.073242  1.556521 
0.146484  1.52818 
0.292969  1.538579 
0.585938  1.559674 
1.171188  1.541349 
2.34375  1.530526 
4.6875  1.557907 
9.375  1.542227 
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Figure A3.61 Pal-PNA50-TAT_CMC_without NaCl 
 
 
 
 
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 18.75  1.440106 
37.5  1.278774 
75  0.951462 
150  0.755962 
300  0.524218 
Conc(μM)  I373/I383 
0.073242  1.491407 
0.146484  1.501707 
0.292969  1.529079 
0.585938  1.528324 
1.171188  1.485904 
2.34375  1.503573 
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Figure A3.62 Pal-PNA50-TAT_CMC_with NaCl 
 
 
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 4.6875  1.510682 
9.375  1.471018 
18.75  1.378507 
37.5  1.133297 
75  0.972155 
150  0.816353 
300  0.687906 
Conc(μM)  I373/I383 
0.036621  1.546954 
0.073242  1.538435 
0.146484  1.552924 
0.292969  1.529204 
0.585938  1.544755 
1.171875  1.548352 
2.34375  1.529075 
4.6875  1.52951 
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Figure A3.63 Ste-PNA50-TAT_CMC_without NaCl 
 
 
 
1
1.1
1.2
1.3
1.4
1.5
1.6
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 9.375  1.529084 
18.75  1.490792 
37.5  1.387451 
75  1.209281 
150  1.053989 
Conc(μM)  I373/I383 
0.036621  1.580941 
0.073242  1.57357 
0.146484  1.580962 
0.292969  1.535655 
0.585938  1.52839 
1.171875  1.5258 
2.34375  1.521326 
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Figure A3.64 Ste-PNA50-TAT_CMC_with NaCl 
 
 
 
0.5
0.7
0.9
1.1
1.3
1.5
1.7
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 4.6875  1.541627 
9.375  1.506571 
18.75  1.365271 
37.5  1.038377 
75  0.819959 
150  0.633239 
Conc(μM)  I373/I383 
0.073242  1.51946 
0.146484  1.476673 
0.292969  1.478724 
0.585938  1.476153 
1.171875  1.483842 
2.34375  1.457541 
4.6875  1.438296 
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Figure A3.65 Lau-PNA5-TAT_CMC_without NaCl 
 
 
 
 
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 9.375  1.433204 
18.75  1.392636 
37.5  1.221884 
75  1.025795 
150  0.877138 
300  0.72958 
Conc(μM)  I373/I383 
0.073242  1.472441 
0.146484  1.468961 
0.292969  1.50234 
0.585938  1.467566 
1.171875  1.441925 
2.34375  1.482727 
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Figure A3.66 Lau-PNA5-TAT_CMC_with NaCl 
 
 
 
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 4.6875  1.446814 
9.375  1.437899 
18.75  1.400976 
37.5  1.352408 
75  1.120911 
150  0.897925 
300  0.773937 
Conc(μM)  I373/I383 
0.036621  1.372476 
0.073242  1.358689 
0.146484  1.361572 
0.292969  1.372267 
0.585938  1.342976 
2.34375  1.335562 
4.6875  1.316505 
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Figure A3.67 Ted-PNA5-TAT_CMC_without NaCl 
 
 
 
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 9.375  1.321656 
18.75  1.28829 
37.5  1.180975 
75  0.996703 
150  0.853303 
Conc(μM)  I373/I383 
0.073242  1.501411 
0.146484  1.524147 
0.292969  1.477427 
0.585938  1.50338 
1.171875  1.485371 
2.34375  1.476161 
4.6875  1.490786 
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Figure A3.68 Ted-PNA5-TAT_CMC_with NaCl 
 
 
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 9.375  1.449708 
18.75  1.360025 
37.5  1.180808 
75  0.922754 
150  0.749952 
Conc(μM)  I373/I383 
0.061035  1.382814 
0.12207  1.42456 
0.244141  1.407194 
0.488281  1.335691 
0.976563  1.337416 
1.953125  1.31787 
3.90625  1.337039 
7.8125  1.346432 
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Figure A3.69 Pal-PNA5-TAT_CMC_without NaCl 
 
 
 
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 15.625  1.331061 
31.25  1.253025 
62.5  1.078024 
125  0.9058 
250  0.786331 
Conc(μM)  I373/I383 
0.061035  1.42754 
0.12207  1.448865 
0.244141  1.446877 
0.488281  1.417716 
0.976563  1.452516 
1.953125  1.431694 
3.90625  1.406524 
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Figure A3.70 Pal-PNA5-TAT_CMC_with NaCl 
 
 
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 7.8125  1.416878 
15.625  1.30522 
31.25  1.119771 
62.5  1.001058 
125  0.84131 
250  0.747721 
Conc(μM)  I373/I383 
0.073242  1.414205 
0.146484  1.397047 
0.292969  1.39251 
0.585938  1.382898 
1.171875  1.381357 
2.34375  1.363379 
4.6875  1.369738 
9.375  1.358316 
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Figure A3.71 Ste-PNA5-TAT_CMC_without NaCl 
 
 
 
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 18.75  1.323311 
37.5  1.204597 
75  1.07821 
150  0.901711 
300  0.735917 
Conc(μM)  I373/I383 
0.073242  1.473574 
0.146484  1.437582 
0.292969  1.457236 
0.585938  1.481257 
1.171875  1.471057 
2.34375  1.4422 
4.6875  1.452284 
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Figure A3.72 Ste-PNA5-TAT_CMC_with NaCl 
 
 
 
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 9.375  1.43741 
18.75  1.382907 
37.5  1.280299 
75  1.182513 
150  0.980553 
300  0.866199 
Conc(μM)  I373/I383 
0.048828  1.407267 
0.097656  1.415206 
0.195313  1.394877 
0.390625  1.39321 
0.78125  1.385847 
1.5625  1.389588 
3.125  1.385841 
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Figure A3.73 Ted-PNA7-TAT_CMC_without NaCl 
 
 
 
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 6.25  1.38606 
12.5  1.340232 
25  1.306131 
50  1.034889 
100  0.870455 
200  0.769697 
Conc(μM)  I373/I383 
0.048828  1.469491 
0.097656  1.409112 
0.195313  1.479408 
0.390625  1.456333 
0.78125  1.457504 
1.5625  1.451384 
3.125  1.44017 
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Figure A3.74 Ted-PNA7-TAT_CMC_with NaCl 
 
 
 
0.5
0.7
0.9
1.1
1.3
1.5
1.7
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 6.25  1.403456 
12.5  1.317163 
25  1.242415 
50  1.028183 
100  0.805606 
200  0.615911 
Conc(μM)  I373/I383 
0.12207  1.373276 
0.244141  1.360979 
0.488281  1.348214 
0.976563  1.323253 
1.953125  1.325216 
3.90625  1.324751 
7.8125  1.319098 
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Figure A3.75 Pal-PNA7-TAT_CMC_without NaCl 
 
 
 
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 15.625  1.310729 
31.25  1.262326 
62.5  1.067739 
125  0.925072 
250  0.781648 
500  0.651409 
Conc(μM)  I373/I383 
0.12207  1.385098 
0.244141  1.415289 
0.488281  1.411881 
0.976563  1.382267 
1.953125  1.401636 
3.90625  1.384779 
7.8125  1.378799 
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Figure A3.76 Pal-PNA7-TAT_CMC_with NaCl 
 
 
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 15.625  1.393228 
31.25  1.337793 
62.5  1.138196 
125  0.888779 
250  0.740145 
500  0.582866 
Conc(μM)  I373/I383 
0.048828  1.444417 
0.097656  1.444014 
0.195313  1.438119 
0.390625  1.43887 
0.78125  1.425487 
1.5625  1.419644 
3.125  1.406051 
6.25  1.406568 
 191 
 
 
Figure A3.77 Ste-PNA7-TAT_CMC_without NaCl 
 
 
 
 
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 12.5  1.407357 
25  1.35944 
50  1.235891 
100  1.052852 
200  0.895853 
Conc(μM)  I373/I383 
0.048828  1.480655 
0.097656  1.451629 
0.195313  1.462045 
0.390625  1.468321 
0.78125  1.439608 
1.5625  1.472842 
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Figure A3.78 Ste-PNA7-TAT_CMC_with NaCl 
 
 
 
 
 
 
 
 
 
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc] (1/Log[μM]) 3.125  1.470755 
6.25  1.438181 
12.5  1.450423 
25  1.334262 
50  1.137911 
100  0.982921 
200  0.742168 
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Figure A3.79 TLC of Br-76 Radiolabling of Pal-PNA50S-TAT conjugate 
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Figure A3.80 TLC of Br-76 Radiolabling of Pal-PNA50-TAT conjugate  
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Figure A3.81 HPLC of Br-76 Radiolabling of Pal-PNA50S-TAT conjugate, detected with UV-vis 
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Figure A3.82 HPLC of Br-76 Radiolabling of Pal-PNA50S-TAT conjugate, detected with 
Radioactivity 
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Figure A3.83 HPLC of Br-76 Radiolabling of Pal-PNA50-TAT conjugate, detected with UV-vis 
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Figure A3.84 HPLC of Br-76 Radiolabling of Pal-PNA50-TAT conjugate, detected with 
Radioactivity 
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Table3.85 Biodistribution of Pal-PNA50-TAT and Pal-PNA50S-TAT conjugates in %ID/organ 
%ID/organ 1 h Pal-PNA50-TAT 1 h Pal-PNA50S-TAT 4 h Pal-PNA50-TAT 
blood 3.5267+/‐0.5914  2.4367+/‐0.5013  3.9401+/‐0.5872 
lung 5.8026+/‐0.7218  2.1946+/‐0.2579  6.8217+/‐1.5773 
liver(all) 110.3009+/‐14.4295  82.2869+/‐1.8715  102.6267+/‐15.5642 
spleen 3.5004+/‐0.6674  2.5148+/‐1.3478  3.7839+/‐0.9115 
kidney 2.5938+/‐0.5978  1.4569+/‐0.0617  4.4577+/‐0.5827 
muscle 8.7607+/‐1.9021  6.4658+/‐0.9508  11.174+/‐1.9442 
heart 0.456+/‐0.08  0.2922+/‐0.0328  0.4349+/‐0.024 
brain 0.0598+/‐0.0178  0.042+/‐0.0116  0.1085+/‐0.0171 
tumor 0.7492+/‐0.6395  0.2705+/‐0.1295  0.5404+/‐0.4389 
%ID/organ 24 h Pal-PNA50-TAT 24 h Pal-PNA50S-TAT 4 h Pal-PNA50S-TAT 
blood 2.1827+/‐0.2305  3.8084+/‐0.4801  3.3665+/‐0.209 
lung 3.0706+/‐0.9454  1.8773+/‐0.038  2.0778+/‐0.7 
liver(all) 85.0893+/‐21.063  65.5309+/‐8.4771  90.9395+/‐4.2751 
spleen 3.4026+/‐1.4098  2.7523+/‐1.5101  2.1899+/‐0.4076 
kidney 4.035+/‐0.6656  1.7806+/‐0.1255  1.5814+/‐0.2333 
muscle 7.7813+/‐0.3184  9.4609+/‐1.0251  6.4026+/‐0.7722 
heart 0.3509+/‐0.0958  0.2853+/‐0.0152  0.2406+/‐0.044 
brain 0.1086+/‐0.0162  0.2056+/‐0.009  0.075+/‐0.0076 
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tumor 0.3431+/‐0.0593  0.5391+/‐0.425  0.3919+/‐0.2019 
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Table3.86 Biodistribution Pal-PNA50-TAT and Pal-PNA50S-TAT conjugates in Sample weight 
(gram) 
wt (gram) 1 h Pal-PNA50-TAT 1 h Pal-PNA50S-TAT 4 h Pal-PNA50-TAT 
blood 0.2676+/‐0.1318  0.3402+/‐0.1999  0.4442+/‐0.0687 
lung 0.1645+/‐0.022  0.1613+/‐0.0288  0.1599+/‐0.0149 
liver(all) 1.1567+/‐0.1603  1.2659+/‐0.1598  1.1437+/‐0.0771 
spleen 0.2317+/‐0.0774  0.2425+/‐0.1292  0.2321+/‐0.0537 
kidney 0.2166+/‐0.0525  0.2191+/‐0.0306  0.2051+/‐0.0283 
muscle 0.1071+/‐0.0093  0.1548+/‐0.0322  0.1269+/‐0.0688 
heart 0.1268+/‐0.0186  0.1368+/‐0.0065  0.1154+/‐0.0132 
brain 0.3213+/‐0.0214  0.358+/‐0.0453  0.3807+/‐0.0788 
tumor 0.56+/‐0.5337  0.2528+/‐0.1334  0.2508+/‐0.1686 
wt (gram) 24 h Pal-PNA50-TAT 24 h Pal-PNA50S-TAT 4 h Pal-PNA50S-TAT 
blood 0.5959+/‐0.1165  0.6094+/‐0.2643  0.3117+/‐0.1327 
lung 0.1888+/‐0.0267  0.1832+/‐0.022  0.2348+/‐0.1029 
liver(all) 1.5309+/‐0.1258  1.4266+/‐0.3498  1.0804+/‐0.0108 
spleen 0.3015+/‐0.1314  0.3085+/‐0.211  0.1665+/‐0.0219 
kidney 0.2504+/‐0.0268  0.2259+/‐0.0545  0.1893+/‐0.0162 
muscle 0.184+/‐0.0321  0.1302+/‐0.0459  0.1492+/‐0.0525 
heart 0.1489+/‐0.0075  0.1382+/‐0.0268  0.12+/‐0.0089 
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brain 0.4008+/‐0.0260  0.4062+/‐0.0192  0.3748+/‐0.0167 
tumor 0.2025+/‐0.0658  0.2674+/‐0.1799  0.2693+/‐0.1199 
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Table3.87 Biodistribution of Pal-PNA50-TAT and Pal-PNA50S-TAT conjugates in %ID/gram 
%ID/gram 1 h Pal-PNA50-TAT 1 h Pal-PNA50S-TAT 4 h Pal-PNA50-TAT 
blood 2.0077+/‐0.3875  1.2354+/‐0.2855  2.2076+/‐0.2674 
lung 35.9718+/‐8.7477  13.7098+/‐0.9727  43.068+/‐11.9152 
liver(all) 96.4465+/‐16.3888  65.5584+/‐6.6643  89.6468+/‐11.7308 
spleen 15.9572+/‐4.1636  10.3434+/‐0.5201  16.816+/‐4.7261 
kidney 12.0081+/‐0.6155  6.7115+/‐0.6675  22.1392+/‐5.1684 
muscle 0.8437+/‐0.1324  0.5579+/‐0.0843  1.0853+/‐0.2669 
heart 3.6537+/‐0.9027  2.1463+/‐0.3253  3.8065+/‐0.5542 
brain 0.1853+/‐0.0498  0.1157+/‐0.0190  0.2909+/‐0.0556 
tumor 1.3930+/‐0.2775  1.1442+/‐0.2775  2.0311+/‐0.3291 
%ID/gram 24h Pal-PNA50-TAT 24h Pal-PNA50S-TAT 4 h Pal-PNA50S-TAT 
blood 1.1626+/‐0.0297  2.2854+/‐0.3606  1.9082+/‐0.1367 
lung 16.0818+/‐2.9766  10.3461+/‐1.2757  9.1070+/‐1.3567 
liver(all) 55.1865+/‐10.764  48.87+/‐18.0399  84.2028+/‐4.7028 
spleen 11.3394+/‐1.901  9.5369+/‐4.0526  13.0865+/‐0.9366 
kidney 16.0446+/‐0.9774  8.3327+/‐2.8174  8.3754+/‐1.2118 
muscle 0.7122+/‐0.0707  0.9701+/‐0.147  0.6185+/‐0.0654 
heart 2.3472+/‐0.5908  2.1027+/‐0.309  2.0043+/‐0.3392 
brain 0.2712+/‐0.0389  0.5066+/‐0.0282  0.2+/‐0.0136 
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tumor 1.7763+/‐0.4275  1.9314+/‐0.2973  1.4332+/‐0.1274 
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Appendix_Chapter 4 
HPLC, UV, MALDI 
 
Figure A4.1 HPLC of Crude PNA480-TAT conjugate 
 
Figure A4.2 UV of PNA480-TAT conjugate 
 
Figure A4.3 MALDI of PNA480-TAT conjugate 
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Figure A4.4 HPLC of Crude Lau-PNA480-TAT conjugate 
 
 
Figure A4.5 UV of Lau-PNA480-TAT conjugate 
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Figure A4.6 MALDI of Lau-PNA480-TAT conjugate 
 
 
Figure A4.7 HPLC of Crude Ted-PNA480-TAT conjugate 
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Figure A4.8 UV of Ted-PNA480-TAT conjugate 
 
Figure A4.9 MALDI of Ted-PNA480-TAT conjugate 
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Figure A4.10 HPLC of Crude Pal-PNA480-TAT conjugate 
 
 
Figure A4.11 UV of Pal-PNA480-TAT conjugate 
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Figure A4.12 MALDI of Pal-PNA480-TAT conjugate 
 
 
Figure A4.13 HPLC of Crude Ste-PNA480-TAT conjugate 
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Figure A4.14 UV of Ste-PNA480-TAT conjugate 
 
 
Figure A4.15 MALDI of Ste-PNA480-TAT conjugate 
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Figure A4.16 HPLC of Crude PNAMM(480)-TAT conjugate 
 
 
Figure A4.17 UV of PNAMM(480)-TAT conjugate 
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Figure A4.18 MALDI of PNAMM(480)-TAT conjugate 
 
 
Figure A4.19 HPLC of Crude PNA240-TAT conjugate 
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Figure A4.20 UV of PNA240-TAT conjugate 
 
 
Figure A4.21 MALDI of PNA240-TAT conjugate 
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Figure A4.22 HPLC of Crude Lau-PNA240-TAT conjugate 
 
 
Figure A4.23 UV of Lau-PNA240-TAT conjugate 
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Figure A4.24 MALDI of Lau-PNA240-TAT conjugate 
 
 
Figure A4.25 HPLC of Crude Ted-PNA240-TAT conjugate 
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Figure A4.26 UV of Ted-PNA240-TAT conjugate 
 
 
Figure A4.27 MALDI of Ted-PNA240-TAT conjugate 
 
 223 
 
 
Figure A4.28 HPLC of Crude Pal-PNA240-TAT conjugate 
 
 
Figure A4.29 UV of Pal-PNA240-TAT conjugate 
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Figure A4.30 MALDI of Pal-PNA240-TAT conjugate 
 
 
Figure A4.31 HPLC of Crude Ste-PNA240-TAT conjugate 
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Figure A4.32 UV of Ste-PNA240-TAT conjugate 
 
 
Figure A4.33 MALDI of Ste-PNA240-TAT conjugate 
 
DLS, CMC 
Conc (μM)  Z‐Ave (d.nm)  PdI 
961.2  211.4  0.706 
451.764  201.2  0.729 
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225.882  219.7  0.483 
112.941  222.2  0.514 
56.4705  205.1  0.382 
28.23525  233.4  0.413 
14.117625  226.5  0.414 
7.0588125  249.6  0.504 
3.52940625  206.3  0.344 
1.764703125  232  0.3802 
0.882351563  242.2  0.333 
0.441175781  252.7  0.422 
0.220587891  284.8  0.435 
0.110293945  390.6  0.415 
0.055146973  482.5  0.467 
0.027573486  454.6  0.411 
0.013786743  496.8  0.585 
0.006893372  618.5  0.512 
0.003446686  543.8  0.584 
0.001723343  601.8  0.576 
0.000861671  639.5  0.547 
0.000215418  611.2  0.518 
0.000107709  725.4  0.523 
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Figure A4.34 Lau-PNA480-TAT_DLS 
 
 
 
 
 
 
 
 
 
 
100
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300
400
500
600
700
800
900
0.00001 0.001 0.1 10 1000
Z‐Avg/Log[Conc] (d.nm/Log[μM]) 2.69272E‐05  803.7  0.558 
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Conc (μM)  Z‐Ave (d.nm)  PdI 
1037.07  218.7  0.722 
259.2675  215.3  0.55 
129.63375  224.8  0.692 
64.816875  213.6  0.401 
32.4084375  216  0.41 
16.20421875  216.7  0.397 
8.102109375  212.4  0.331 
4.051054688  240.8  0.433 
2.025527344  234  0.355 
1.012763672  246.7  0.442 
0.506381836  275.4  0.432 
0.253190918  302.8  0.497 
0.126595459  320.7  0.523 
0.063297729  435.4  0.482 
0.031648865  414  0.442 
0.015824432  546.3  0.552 
0.007912216  688.1  0.652 
0.003956108  719  0.679 
0.001978054  670.9  0.577 
0.000989027  848.5  0.662 
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Figure A4.35 Ted-PNA480-TAT_DLS 
 
 
 
 
 
 
 
 
 
 
100
200
300
400
500
600
700
800
900
0.00001 0.001 0.1 10 1000
Z‐Avg/Log[Conc] (d.nm/Log[μM]) 0.000494514  769.6  0.572 
0.000123628  808.3  0.617 
6.18142E‐05  766.6  0.623 
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Figure A4.36 Pal-PNA480-TAT_DLS 
 
 
 
 
 
 
 
 
 
 
300
400
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600
700
800
0.0001 0.01 1 100
Z‐Avg/Log[Conc] (d.nm/Log[μM]) Conc (μM)  Z‐Ave (d.nm)  PdI 
710.94  497.2  0.572 
334.1418  488  0.476 
167.0709  477.2  0.583 
83.53545  471.7  0.625 
20.883863  468.3  0.698 
10.441931  474.3  0.637 
5.2209656  426.3  0.584 
2.6104828  443.8  0.692 
1.3052414  475.3  0.547 
0.3263104  415.5  0.649 
0.1631552  443.5  0.52 
0.0815776  498.7  0.462 
0.0407888  584.6  0.611 
0.0203944  653.4  0.696 
0.0101972  658.9  0.678 
0.0050986  693.6  0.531 
0.0025493  693.5  0.626 
0.0006373  711.5  0.536 
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Figure A4.37 Ste-PNA480-TAT_DLS 
 
 
 
 
 
 
 
 
 
 
0
200
400
600
800
1000
1200
1400
1600
0.001 0.01 0.1 1 10 100 1000
Z‐Ave/Log[Conc] (d.nm/Log[μM]) Conc (μM)  Z‐Ave (d.nm)  PdI 
901.728  181.7  PdI 
423.81216  112.7  0.797 
211.90608  132.1  0.734 
105.95304  195.1  0.481 
52.97652  198.7  0.397 
26.48826  210.9  0.35 
13.24413  235.6  0.548 
6.622065  212.7  0.453 
3.3110325  284.6  0.348 
1.65551625  283.5  0.391 
0.827758125  322.5  0.508 
0.413879063  381.6  0.391 
0.206939531  525.2  0.49 
0.103469766  586.9  0.582 
0.051734883  829.7  0.632 
0.025867441  732.3  0.585 
0.012933721  871.4  0.662 
0.00646686  1217  0.675 
0.00323343  999.6  0.62 
0.001616715  1405  0.697 
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Figure A4.38 Lau-PNA240-TAT_DLS 
 
 
 
 
 
 
 
 
 
 
200
300
400
500
600
700
800
900
1000
0.00010.001 0.01 0.1 1 10 100 1000 10000
Z‐Avg/Log[Conc] (d.nm/Log[μM]) Conc (μM)  Z‐Ave (d.nm)  PdI 
1233.255  299.2  0.559 
579.62985  316.2  0.571 
289.814925  320.2  0.493 
144.9074625  338.1  0.546 
72.45373125  337.1  0.447 
36.22686563  309.1  0.597 
18.11343281  326.2  0.461 
9.056716406  341.3  0.488 
4.528358203  415.2  0.647 
2.264179102  469  0.655 
1.132089551  460.1  0.473 
0.566044775  540.2  0.624 
0.283022388  487.2  0.494 
0.141511194  566.2  0.564 
0.070755597  506.4  0.581 
0.035377798  528.5  0.501 
0.004422225  744.5  0.559 
0.002211112  746.9  0.59 
0.000276389  929.9  0.723 
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Conc (μM)  Z‐Ave (d.nm)  PdI 
1162.332  212.3  0.489 
546.29604  206.5  0.462 
273.14802  203.6  0.404 
136.57401  209.4  0.526 
68.287005  220.5  0.422 
34.1435025  232.3  0.529 
17.07175125  245.1  0.374 
8.535875625  274  0.45 
4.267937813  297.2  0.412 
2.133968906  326.3  0.467 
1.066984453  312.2  0.506 
0.533492227  353.1  0.492 
0.266746113  368.6  0.517 
0.133373057  433.7  0.538 
0.066686528  436.8  0.554 
0.033343264  660.7  0.489 
0.016671632  522  0.573 
0.008335816  658.8  0.594 
0.004167908  684.7  0.649 
0.001041977  961.1  0.486 
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Figure A4.39 Ted-PNA240-TAT_DLS 
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900
1100
0.0001 0.01 1 100
Z‐Ave/Log[Conc] (d.nm/Log[μM]) 0.000520989  909  0.593 
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Conc (μM)  Z‐Ave (d.nm)  PdI 
981  590.5  0.59 
461.07  570.8  0.576 
230.535  540.2  0.573 
115.2675  522  0.531 
57.63375  513  0.622 
7.20421875  569  0.766 
3.60210938  409.8  0.774 
1.80105469  318.1  0.551 
0.90052734  320.3  0.555 
0.45026367  331.5  0.56 
0.22513184  310.2  0.458 
0.11256592  378  0.487 
0.05628296  409.6  0.562 
0.02814148  349.8  0.477 
0.01407074  461.4  0.418 
0.00703537  472.3  0.582 
0.00351768  554  0.545 
0.00175884  524.1  0.595 
0.00087942  586.8  0.505 
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Figure A4.40 Pal-PNA240-TAT_DLS 
 
 
 
 
 
200
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600
700
800
0.0001 0.01 1 100
Z‐Avg/Log[Conc] (d.nm/Log[μM]) 0.00043971  705.5  0.527 
Conc (μM)  Z‐Ave (d.nm)  PdI 
1160.36  202  0.602 
545.3692  187.8  0.728 
272.6846  188.9  0.538 
136.3423  213.4  0.559 
68.17115  254.4  0.667 
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Figure A4.41 Ste-PNA240-TAT_DLS 
 
 
 
  
100
200
300
400
500
600
700
0.001 0.1 10 1000
Z‐Ave /Log[Conc] (d.nm/Log[μM]) 34.085575  245.1  0.418 
17.0427875  278.9  0.499 
4.260696875  285.6  0.539 
2.130348438  331.7  0.433 
1.065174219  466.2  0.592 
0.532587109  509.4  0.618 
0.266293555  408.2  0.649 
0.133146777  587  0.594 
0.008321674  635.9  0.577 
0.004160837  576.1  0.657 
0.002080418  599.2  0.582 
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Figure A4.42 Lau-PNA480-TAT_CMC_without NaCl 
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1.4
1.5
1.6
1.7
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc]  (1/Log[μM])   Conc(μM)  I373/I383 
0.073242  1.581367 
0.146484  1.588811 
0.292969  1.588511 
0.585938  1.56073 
1.171875  1.593696 
2.34375  1.581242 
4.6875  1.570455 
9.375  1.551768 
18.75  1.479367 
37.5  1.266285 
75  1.13928 
150  0.980921 
Conc(μM)  I373/I383 
0.073242  1.556655 
0.146484  1.574758 
0.292969  1.562281 
0.585938  1.570605 
1.171875  1.576465 
2.34375  1.534323 
4.6875  1.528656 
9.375  1.509151 
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Figure A4.43 Lau-PNA480-TAT_CMC_with NaCl 
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0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc]  (1/Log[μM])   18.75  1.428272 
37.5  1.232477 
75  1.046993 
150  0.863893 
300  0.691212 
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Figure A4.44 Ted-PNA480-TAT_CMC_without NaCl 
 
 
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
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1.6
0.01 0.1 1 10 100 1000
I373/I383‐Log[Conc]  (1/Log[μM])   Conc(μM) I373/I383 
0.097656 1.454661 
0.195313 1.454277 
0.390625 1.450867 
0.78125 1.456246 
1.5625 1.436909 
3.125 1.444806 
6.25 1.437723 
12.5 1.424193 
25 1.39823 
50 1.327589 
100 1.240088 
200 1.086773 
400 0.818406 
Conc(μM)  I373/I383 
0.036621  1.526893 
0.073242  1.536426 
0.146484  1.529303 
0.292969  1.541453 
0.585938  1.520196 
1.171875  1.54228 
2.34375  1.536197 
4.6875  1.541397 
9.375  1.4796 
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Figure A4.45 Ted-PNA480-TAT_CMC_with NaCl 
 
 
  
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
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I373/I383‐Log[Conc]  (1/Log[μM])   18.75  1.411491 
37.5  1.197306 
75  0.951847 
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Figure A4.46 Pal-PNA480-TAT_CMC_without NaCl 
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I373/I383‐Log[Conc]  (1/Log[μM])   Conc(μM)  I373/I383 
0.097656  1.464744 
0.195313  1.460314 
0.390625  1.464765 
0.78125  1.475964 
1.5625  1.440084 
3.125  1.441263 
6.25  1.444291 
12.5  1.432693 
25  1.35777 
50  1.254159 
100  1.106794 
200  0.983272 
400  0.831756 
Conc(μM)  I373/I383 
0.097656  1.459827 
0.195313  1.456325 
0.390625  1.405575 
0.78125  1.442397 
1.5625  1.442334 
3.125  1.432144 
6.25  1.411607 
12.5  1.386513 
25  1.266136 
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Figure A4.47 Pal-PNA480-TAT_CMC_with NaCl 
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Figure A4.48 Ste-PNA480-TAT_CMC_without NaCl 
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I373/I383‐Log[Conc]  (1/Log[μM])   Conc(μM)  I373/I383 
0.073242  1.449829 
0.146484  1.443933 
0.292969  1.458856 
0.585938  1.44262 
1.171875  1.447509 
2.34375  1.442779 
4.6875  1.420226 
9.375  1.399392 
18.75  1.31609 
37.5  1.188901 
75  1.042792 
150  0.905043 
300  0.765537 
Conc(μM)  I373/I383 
0.073242  1.579493 
0.146484  1.541111 
0.292969  1.565289 
0.585938  1.524181 
1.171875  1.51309 
3.34375  1.554108 
4.6875  1.530509 
9.375  1.494318 
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Figure A4.49 Ste-PNA480-TAT_CMC_with NaCl 
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I373/I383‐Log[Conc]  (1/Log[μM])   18.75  1.415011 
37.5  1.259409 
75  0.914326 
150  0.68944 
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Figure A4.50 Lau-PNA240-TAT_CMC_without NaCl 
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I373/I383‐Log[Conc]  (1/Log[μM])   Conc(μM)  I373/I383 
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0.12207  1.566195 
0.244141  1.576519 
0.488281  1.56004 
0.976563  1.578724 
1.953125  1.572363 
3.90625  1.556951 
7.8125  1.574057 
15.625  1.572917 
31.25  1.534576 
62.5  1.422072 
125  1.267044 
250  1.084923 
Conc(μM)  I373/I383 
0.061035  1.510399 
0.12207  1.507151 
0.244141  1.482771 
0.488281  1.491031 
0.976563  1.490182 
1.953125  1.465297 
3.90625  1.436136 
7.8125  1.452792 
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Figure A4.51 Lau-PNA240-TAT_CMC_with NaCl 
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Figure A4.52 Ted-PNA240-TAT_CMC_without NaCl 
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I373/I383‐Log[Conc]  (1/Log[μM])   Conc(μM)  I373/I383 
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Figure A4.53 Ted-PNA240-TAT_CMC_with NaCl 
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Figure A4.54 Pal-PNA240-TAT_CMC_without NaCl 
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Figure A4.55 Pal-PNA240-TAT_CMC_with NaCl 
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Figure A4.56 Ste-PNA240-TAT_CMC_without NaCl 
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Figure A4.57 Ste-PNA240-TAT_CMC_with NaCl 
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Figure A4.58 Griess Assay of iNOS Inhibition by Lipid-PNA480-TAT, PNA480-TAT and 
PNA480-Lys4 conjugates 
 
 
 
 
Figure A4.59 Cell Viability Assay of Lipid-PNA480-TAT, PNA480-TAT and  
PNA480-Lys4 conjugates 
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Figure A4.60 Griess Assay of iNOS Inhibition by Ste-PNA480-TAT and Pal-PNA480-TAT 
conjugates with different concentrations of Lipo 
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Figure A4.61 Cell Viability of Ste-PNA480-TAT and Pal-PNA480-TAT conjugates with different 
concentrations of Lipo 
 
